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1. ABBREVIATIONS 
 
BMI = body mass index 
CI = confidence interval 
COC = combined oral contraceptive  
DMPA = depot medroxyprogesterone acetate 
HCP = health care provider 
ICD-10 = International Classification of Diseases 2010 
IUC = intrauterine contraception 
IUD = intrauterine device 
LAM = lactational amenorrhoea method 
LARC = long-acting reversible contraception 
LNG = levonorgestrel 
LNG-IUS = levonorgestrel-releasing intrauterine system 
                  (52 mg, 20 µg/24 h)  
LNG-IUS 13.5 mg = levonorgestrel-releasing intrauterine system  
                               (13.5 mg, 12 µg/24 h) 
NOMESCO = Nordic Medico-Statistical Committee  
NSAID = non-steroidal anti-inflammatory drug 
OR = odds ratio 
PCB = paracervical block 
PID = pelvic inflammatory disease 
ROC = Receiver Operating Characteristic 
STD = sexually transmitted disease 
STM = Ministry of Social Affairs and Health 
THL = National Institute for Health and Welfare 
UN = United Nations 
WHO = World Health Organization 
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3. ABSTRACT 	  
The proportion of nulligravid and nulliparous women is increasing as 
women delay childbirth in developed countries. Simultaneously, 
contraceptive failure, unintended pregnancies and abortions, especially 
in women below the common childbearing age, are a global problem. By 
promoting intrauterine devices (IUDs) and subdermal implants, referred 
to as long-acting reversible contraceptives (LARCs), among these 
women, contraceptive failure caused by non-compliance of the user can 
be minimized, in addition to providing easy and efficient long-term 
contraception. However, the risk of difficulties at IUD insertion in 
nulligravid/nulliparous women, as well as small uterine size, have both 
been considered as barriers limiting the use of intrauterine contraception 
(IUC) in these women. 
The present studies were designed to study the barriers to 
IUC in nulligravid and nulliparous women. To compare both types of IUC 
available, we used the levonorgestrel-releasing intrauterine system 
(LNG-IUS) and the copper-releasing NovaT (TCu380Ag), with identical 
frames measuring 32 x 32 mm. To exclude any effect of prior pregnancy 
on the uterine cavity or the cervix, only nulligravid women were included. 
Difficulties at insertion, menstrual diaries kept after insertion (months 1–
3) and at the end of the study (months 10–12) as well as adverse events 
were compared against uterine cavity measurements and pre-insertion 
menstrual characteristics reported by the women. In addition, as uterine 
perforation is mainly seen as a complication related to insertion, we 
retrospectively analysed women treated for this rare complication 
between 1996 and 2009 in our hospital district area. 
We gave 165 nulligravid women requesting their first IUD a 
free choice between the two IUDs after contraceptive counselling. The 
majority, 113 women (68.5%), chose the LNG-IUS and 52 women 
(31.5%) chose the copper IUD. Insertion was easy in 89% of the 
women. The women were satisfied, with only 17/135 women (12.6%) 
available for follow-up discontinuing because of adverse events. The 
reported numbers of days of bleeding and pain were similar to that in 
earlier reports on parous women.  Severe pain at insertion was reported 
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by 56.5% of the women and severe dysmenorrhoea the only factor 
predicting severe pain (OR 7.9, 95% CI 2.5–24.9, p<0.001). 
Dysmenorrhoea was also related to more pain during the first months 
with both devices. Baseline spontaneous bleeding predicted bleeding 
with the LNG-IUS, but not with the copper IUD. Among women using the 
LNG-IUS, scanty menstrual bleeding (OR 8.2, 95% CI 1.4–48.2, p=0.02) 
and smoking (OR 8.2, 95% CI 1.8–38.6, p=0.007) predicted 
amenorrhoea at one year. Uterine measurements, particularly fundal 
cavity width, were small in comparison to the devices in a majority of the 
women. The odds of a difficult or failed insertion increased with shorter 
uterine length and a steeper flexion angle, but the great majority of 
insertions, even in small and more flexed uteri, were uneventful.  
Cervical tightness was the main reason for problems in cases of difficult 
insertion. No uterine threshold measurements predicting difficulties were 
found. Small uterine measurements were associated with both less 
bleeding and less pain among LNG-IUS users. Women with the widest 
fundal widths reported significantly more pain at the end of the one-year 
follow-up period compared with those with smaller widths. Uterine size 
did not affect bleeding in connection with the copper IUD, but there was 
a slight tendency towards more pain during long-term use among 
women with smaller uterine cavity measurements, although size groups 
were small with this device. Uterine size did not predict adverse events.  
We found 75 cases of surgically treated uterine perforation 
during the 15–year long study period. The incidence of perforation was 
low, 0.4/1000 insertions, and similar with both types of IUC. Postpartum 
insertion, earlier presented as the main risk factor of uterine perforation, 
was also common in this population (64%). The majority of cases, 71%, 
presented with complaints of abnormal bleeding or pain, but 29% were 
asymptomatic and diagnosed in connection with missing threads or 
pregnancy.  Pregnancy was more common with a misplaced copper 
IUD, 33% vs. 7% with a misplaced LNG-IUS (p=0.009). We found no 
severe complications or intra-abdominal adhesions caused by the 
misplaced devices. Adhesions were local and more common in copper 
IUD users (58% vs. 20%, p=0.002). 
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In conclusion, nulligravid women are satisfied users of 
modern IUC, with continuation rates and bleeding and pain profiles 
similar to those in parous women. Small uterine cavity measurements 
are not a barrier to IUC and pre-insertion ultrasonographic evaluation of 
uterine cavity size is unnecessary. As dysmenorrhoea predicts both 
severe insertion pain and pain during the first months of IUD use, 
analgesia and counselling for these women should be highlighted. 
Although rare, the risk of uterine perforation is increased during the 
postpartum period, probably reflecting uterine involution as the main 
reason for this complication. Neither symptoms nor surgical findings are 
severe in connection with current devices.  
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4. INTRODUCTION 
 
Fertile-aged women are divided by parity in gynaecological literature. A 
parous woman has delivered a child, either vaginally or by Caesarean 
section. A nulliparous woman has not delivered a child, but may have 
had a prior spontaneous abortion or termination of pregnancy. 
Nulligravid women are a subgroup of nulliparous women with no prior 
history of pregnancy.  
The history of intrauterine contraception (IUC) has seen 
intrauterine devices (IUDs) of different sizes and shapes. Results with 
these devices have not always been beneficial for nulliparous women. 
The increased rate of pelvic inflammatory disease (PID) and subsequent 
infertility linked to IUC in nulliparous women during the 1970s harmed 
the reputation of IUC for decades. In addition, small uterine size in these 
women, causing problems during IUD insertion and use, has been a 
constant concern among physicians. Thus, IUDs were recommended 
only for parous women for decades (Toivonen and Luukkainen 1987). 
With the introduction of the levonorgestrel-releasing intrauterine system 
(LNG-IUS) in the 1990s, the additional therapeutic benefits of the device 
have resulted in widespread promotion of the use of IUC. 
The proportion of nulligravid/nulliparous women of 
reproductive age is increasing, as all developed countries have seen a 
constant increase in the age at first delivery as well as an increase in 
women choosing to remain childless (Oliveira da Silva et al. 2011, 
OECD 2011-2014, THL 2014a,). Women of all ages and parities have 
higher satisfaction and continuation rates with long-acting reversible 
contraception (LARC), including IUDs and subdermal implants, than with 
other methods (O’Neil-Callahan et al. 2013). With high rates of 
contraceptive failure and consequently unintended pregnancies and 
abortions globally, especially in young women, the importance of LARC 
has been highlighted during the last decade (ACOG 2012, Winner et al. 
2012, CDC 2013, NICE 2014). Increased concerns regarding 
cardiovascular and thromboembolic health risks caused by combined 
hormonal contraception (Lidegaard et al. 2009, Bitzer et al. 2013) have 
additionally promoted the use of oestrogen-free contraceptives. 
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When the present studies were planned, only a handful of studies on 
nulligravid/nulliparous women using the LNG-IUS had been published. 
Conclusions from studies on copper IUDs in these women were 
skeptical, as the history of copper IUDs has seen higher rates of 
discontinuation in these women. Smaller uterine size in these women 
was linked to reports of adverse events and was considered as a barrier 
limiting the use of IUDs, in addition to historical safety concerns and 
higher rates of problematic insertions.  
Studying uterine size in relation to successful IUD insertion 
and long-term use was the initial objective for the present studies. As 
pregnancy increases uterine size (Kurz et al. 1984), only nulligravid 
women were included in order to exclude any effect pregnancy may 
have on the uterine cavity or the cervix. To evaluate other potential 
factors related to problems at insertion or during long-term use, 
background characteristics were analysed. In addition, as uterine 
perforation is mainly seen as a complication related to insertion, and 
problematic insertions are more common in nulligravid/nulliparous 
women, we analysed patient characteristics and the clinical course of 
women treated for this rare complication in our hospital district area.  
 14	  
5. REVIEW OF THE LITERATURE 
 
Intrauterine contraception 
 
Development  
 
Inert and copper-releasing devices 
The history of modern intrauterine contraception started in the 1920s, 
when a German, Dr. Gräfenberg, described an intrauterine ring made of 
silkworm gut and silver filaments and later found to contain copper. 
Endemic gonorrhoea, commonly causing infections, together with the 
political atmosphere in Germany condemning contraception, prevented 
the intrauterine ring from gaining popularity (Thiery 2000). Intrauterine 
contraception gained popularity in the 1960s. The first IUDs, including 
the popular s-shaped Lippes loop, were inert plastic devices, depending 
on a large size and surface area for an adequate contraceptive effect. 
Problems with bleeding and expulsion were common (Kurz et al. 1984). 
The first T-shaped IUD was developed by Dr. Tatum in the 1960s to fit 
the uterine cavity better and reduce problems associated with the 
devices (Thiery 2000). Side-effects were reduced, but pregnancy rates 
were high. By adding copper to the device, pregnancy rates could be 
reduced (Zipper et al. 1971) and thus the first copper-T IUD was 
introduced in 1974. Since then, a variety of devices of different shapes 
and sizes have been available. As T-shaped devices containing 380 
mm2 of copper (TCu380) have proven to be most effective and user-
friendly (O’Brien et al. 2008), IUDs of other shapes have gradually been 
withdrawn, although T-models containing less copper are still available. 
In addition to the T-models, a frameless device, designed to better fit the 
uterine cavity and thus further reduce side-effects is available, but trials 
comparing this device with the TCu380 models have not verified its 
superiority (O’Brien and Maarfleet 2005, Meirik et al. 2009).  
The inert plastic U-shaped Dalkon shield, introduced in 
1970, greatly damaged the reputation of intrauterine contraception, 
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especially in young and nulligravid/nulliparous women, as unintended 
pregnancies resulting in septic abortions and deaths, and increased 
rates of infertility were described. Infections were later found to be the 
result of vaginal bacteria reaching the uterine cavity through the 
multifilament nylon thread used only in this device and infertility was a 
result of the infections (Tatum 1975). The device was withdrawn in 1974 
after multiple lawsuits.  
 
Hormonal intrauterine contraception 
The first hormonal IUD was developed in the 1960s. By adding 
progesterone to an inert T-shaped plastic frame, the hope was to reduce 
uterine contractility and thus reduce expulsion rates.  Instead, 
contraceptive efficacy was increased (Pharris et al. 1974) and menstrual 
blood loss reduced (Bergkvist and Rybo 1983). To lengthen the lifespan 
of the device, progesterone was replaced by levonorgestrel (LNG). The 
result was the LNG-IUS, made by adding a steroid reservoir covered 
with a silastic membrane onto the vertical arm of the frame of the copper 
device NovaT. The device was developed in Finland and introduced to 
the Finnish market in 1990 as the first country in the world. 
The LNG-IUS has since gained increasing popularity owing 
to its additional therapeutic health benefits. The contraceptive effect is 
comparable to sterilization (Andersson et al. 1994). The reduction in 
menstrual blood loss and lower abdominal pain has widened indications 
to menorrhagia, dysmenorrhoea, adenomyosis and endometriosis and 
thus reduced the need for hysterectomy. The therapeutic effect on the 
endometrium has proven beneficial in treating hyperplasia and 
protecting the endometrium during hormone replacement therapy 
(Andersson and Rybo 1990, Heikinheimo and Gemzell-Danielsson 
2012).  
To further reduce systemic exposure and progestin-related 
side-effects and to improve user satisfaction, a smaller LNG-IUS, the 
LNG-IUS 13.5 mg, designed for women with a small uterine cavity and 
to facilitate insertion in women with a tighter cervical canal, namely 
nulliparous women, has recently been introduced (Gemzell-Danielsson 
et al. 2012). 
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Mechanisms of action 
 
Copper-releasing devices  
When using a copper-releasing IUD, copper accumulates throughout the 
epithelium of the uterine cavity and fallopian tubes (Gemzell-Danielsson 
et al. 2013a) and concentrations are high enough to be toxic to both 
gametes and fertilized embryos (Ortiz and Croxatto 2007). Copper ions 
released from the device cause a local inflammatory response, 
disturbing the endometrial lining of the implantation site (Savaris et al. 
2000). Copper also increases contractility of both the fallopian tubes and 
the myometrium (Gemzell-Danielsson et al. 2013a).  
The main contraceptive effect of a copper IUD is attributed 
to prevention of fertilization, but in the event of fertilization also to the 
prevention of formation of viable embryos, and inhibition of implantation 
(Gemzell-Danielsson et al. 2013a). Markedly reduced incidences of 
implantation signs in women using copper IUDs in comparison with 
controls support this (Videla-Rivero et al. 1987). These mechanisms 
also make a copper device the most effective form of emergency 
contraception up to five days after unprotected sexual intercourse 
(Gemzell-Danielsson et al. 2013a).  
The levonorgestrel-releasing intrauterine system 
The constant local release of LNG results in endometrial concentrations 
significantly higher than with systemic methods and a subsequent 
endometrial suppression (Nilsson et al. 1982). Decidualization of the 
endometrium results in unresponsiveness to oestrogen (Jones et al. 
2000, Luukkainen et al. 2001). Although histological changes are rapid 
and seen within one month after insertion of the device, some secretory 
activity can be seen during the first few months of use. The inflammatory 
response to the device also decreases within six months post-insertion 
(Jones et al. 2000). These gradual changes are often seen as irregular 
bleeding or spotting during the first three to four months of use and 
thereafter a gradual reduction of menstrual blood loss during the first 
year in seen (Luukkainen et al. 2001). 
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Concentrations of LNG in the myometrium and plasma are 
low, but not absent (Nilsson et al. 1982). Thus, hormonal side-effects, 
such as acne, weight change, breast tenderness and mood changes are 
seen in 1–2% of women (Luukkainen et al. 2001). Effects on ovulation 
are minimal during long-term use, with the majority of cycles being 
ovulatory (Nilsson et al. 1984). However, shortly after insertion, when 
LNG plasma concentrations are at their highest, many women have 
anovulatory cycles (Nilsson et al. 1980, Järvelä et al. 1998).  
The cervical mucus becomes thick and impermeable, 
preventing sperm penetration into the uterus (Luukkainen et al. 2001). 
Current understanding also indicates prevention of fertilization, but the 
mechanism is still unclear (Ortiz and Croxatto 2007). 
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Global use of intrauterine contraception 
 
According to the United Nations (UN) World Contraceptive Report in 
2013, 14% of women who are married or cohabiting worldwide use 
intrauterine contraception. In parts of Asia the prevalence exceeds 40%, 
in Europe the prevalence is 12%, in Northern America 5%, in Latin 
America 7%, in Northern Africa 20% and in Sub-Saharan Africa only 
0.5%. However, large regional differences exist and the prevalence in 
Africa and Asia is strongly dependent of the socio-economic status of 
the region (UN World Contraceptive report 2013). Prevalence increases 
with age and women under the age of 20 rarely use intrauterine 
contraception – national reports show rates of 0–3% (CDC 2010, 
Oliveira da Silva et al. 2011, NHS 2013/14, Läkemedelsverket i Sverige 
2014). Figure 1 summarizes the prevalence of intrauterine contraception 
in European and other major countries. 
IUDs are the most commonly used reversible contraceptives 
globally, while female sterilization has the largest prevalence overall 
(D’Arcangues 2007). In most developed countries the oral contraceptive 
pill, combined (COC) or progestin-only, and condoms are the most 
popular forms of contraception. This is also true in Finland, with 31% of 
fertile-aged women reporting using COCs or progestin pills. Intrauterine 
contraception and condoms are equally popular in second place, with a 
prevalence of 23% (Oliveira da Silva et al. 2011). The popularity of the 
LNG-IUS has steadily increased since its introduction and it currently 
represents approximately 85% of IUDs inserted in Finland annually 
(Oliveira da Silva et al. 2011).  
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Figure 1. Percentage of women aged 15–49 years using any IUD as 
contraception. Numbers are based on statistics from 2007–2011 according to 
availability by each country. Data from the Oliveira da Silva et al. 2011 and UN 
World Contraceptive report 2013. 	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Benefits of intrauterine contraception 
 
Long-acting reversible contraception 
 
Contraceptive methods can be divided into long-acting (LARC) and 
short-acting reversible methods (Table 1). Short-acting contraceptives 
are taken daily, weekly or monthly and require the user to be compliant. 
Long-acting contraceptives are not user-dependent and can be used 
continuously from 3–10 years without the need of continuous 
compliance. Additional methods commonly not included in the 
categories above include the lactational amenorrhoea method (LAM), 
sterilization, withdrawal and fertility-based awareness methods, where 
unprotected sexual intercourse is avoided on fertile days of the cycle. 
LAM is effective when the woman is amenorrhoeic, fully or nearly fully 
breastfeeding and less than six months post-partum and is widely used 
in developing countries. Withdrawal and fertility-based awareness 
methods are not recommended, as failure rates are high (WHO 2010, 
Trussell 2011). 
 
 
Table 1. Modern contraceptive methods.  
Long-acting methods Short-acting methods 
IUDs         LNG-IUS (hormonal) Hormonal methods 
                Copper IUDs      Combined*        Pill  
                                Patch 
Subdermal implant 
                Progestin releasing 
                               Vaginal ring 
                               Injection 
      Progestin only   Pill 
                               Injection (DMPA**) 
 Barrier methods 
      Diaphragm/sponge 
      Condom 
      Spermicide 
IUD = intrauterine device, LNG-IUS = levonorgestrel-releasing intrauterine system, 
*Oestrogen + progestin, **DMPA = depot medroxyprogesterone acetate 
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User compliance and contraceptive efficacy  
 
With high rates of unintended pregnancies and abortions globally, the 
importance of LARC has been highlighted during the last decade. In the 
U.S. 50% of all pregnancies are estimated to be unintended and half of 
these result from contraceptive failure (Winner et al. 2012). One in five 
of these unintended pregnancies occur in adolescents (ACOG 2012). 
The contraceptive efficacy of all available methods is high when used 
adequately, but problems with user compliance (forgetting pills, patches, 
rings or injections or inadequate use of non-hormonal methods) raise 
failure rates markedly (Table 2). 
Problems with compliance, and thus risk for unintended 
pregnancy, is twice as high in women ≤ 20 years of age (Kost et al. 
2008, Winner et al. 2012). Among these highly fertile and sexually active 
women, contraceptive counselling and provision of efficient and effective 
methods is crucial. In Finland adolescent pregnancy rates are low as a 
result of increased education, contraceptive counselling and provision of 
contraceptives. As LARC methods are non user-dependent, failure rates 
are low (Winner et al. 2012) and continuation at one and two years 
significantly higher than with other methods in all age groups (Peipert et 
al. 2011, O’Neil-Callahan et al. 2013). The Contraceptive CHOICE 
project, providing contraceptive counselling and any preferred 
contraceptives cost-free in the U.S., includes extensive studies 
confirming the benefits of LARC in reducing the costs and subjective 
burden of unintended pregnancy and as well as acceptance of IUDs in 
women of all ages, including adolescents (McNicholas et al. 2014, 
Contraceptive CHOICE project).  
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Table 2. Pregnancy rates (n/100) with different family planning methods during 
the first year of use and continuation rates after one year. 
Method Typical use Perfect use Continuation rate  
No contraception 85 85  
Spermicides 29 18 42 
Withdrawal 27 4 43 
Fertility awareness-based 
methods (several) 
25 3-5 51 
Sponge       Parous women 32 20 46 
                   Nulliparous women 16 9 57 
Diaphragm 16 6 57 
Condom      Male 15 2 53 
                   Female 21 5 49 
Pill (combined and progestin-
only) 
8 0.3 68 
Patch 8 0.3 68 
Vaginal ring 8 0.3 68 
Injection      Progestin (DMPA) 3 0.3 56 
                   Combined  3 0.05 56 
IUD     LNG-IUS 0.2 0.2 80 
           Copper T  0.8 0.6 78 
Subdermal implant 0.05 0.05 84 
Sterilization      Male 0.15 0.10 100 
                         Female 0.5 0.5 100 
Lactational amenorrhoea 
method* 
- 0.5-1.5 - 
World Health Organization 2010, *Trussell 2011  
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Safety of intrauterine contraception  
 
Insertion  
 
Modern IUDs are not only a result of development to increase user 
satisfaction and contraceptive efficacy, but also to facilitate insertion. 
Recent reviews on IUD insertion emphasize that insertions in 
nulligravid/nulliparous women should be considered clinical routine. 
Although cervical tightness is more likely in nulligravid/nulliparous 
women, difficulties may be encountered at IUD insertion in any woman 
(Bahamondes et al. 2014, Kaunitz and Nelson 2014). The proportion of 
difficult insertions in studies among women of different parities is 10–
20%, with numbers somewhat smaller in parous women than in 
nulligravid/nulliparous women and few women requiring cervical 
dilatation, regardless of parity (Brockmeyer et al. 2008, Jensen et al. 
2008, Bahamondes et al. 2011b, Marions et al. 2011, Bahamondes et 
al. 2014, Kaunitz and Nelson 2014). Adolescence does not increase the 
risk of difficulties (Bayer et al. 2012).  The mode of delivery in parous 
women may influence insertion, as women with Caesarean section 
deliveries generally have a tighter cervical canal, comparable to that in 
nulligravid/nulliparous women, and the Caesarean section scar may 
cause uterine distortion (Bahamondes et al. 2011b).  
Difficulties at insertion are mainly related to cervical 
tightness, but also to the experience of the health care provider (HCP). 
To ensure optimal results at IUD insertion, adequate training of HCPs 
and a good technique are is emphasized, as an inexperienced HCP 
(≤10 insertions annually) is a risk factor as regards both difficulties at 
insertion and uterine perforation (Harrison-Woolrych et al. 2003, Zhou et 
al. 2003). Recommended technical aspects to ensure optimal results at 
insertion are summarized in Table 3.  
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Table 3. Summary of technical recommendations for IUD insertion.  
Counselling and verbal anaesthesia  
Most effective in reducing both pain and anxiety.  
No current evidence supporting prophylactic pharmacological pain 
management. 
 
Bimanual pelvic examination 
Anatomy, uterine position and size, rule out infection. 
 
Bivalve speculum examination 
Proper visualization of the cervix, rule out visible cervicitis, providing space for 
insertion. 
 
Use of metallic tenaculum 
Stabilizing the uterus and straightening uterine flexion. 
 
Uterine sounding prior to insertion 
Exploration of the cervical canal, determining uterine depth. 
 
Cervical dilatation 
Not recommended routinely as mechanical dilatation causes pain and 
vasovagal reactions. When needed, para- or intracervical block is 
recommended.  
 
Knowledge of insertion guidelines for each device 
The insertion technique for each device differs somewhat.  
Bahamondes et al. 2014, Kaunitz and Nelson 2014 
 
 
Severe pain at insertion is more common in nulligravid/nulliparous 
women, 14–21%, compared with 5–11% in parous women (Suhonen et 
al. 2004, Hubacher et al. 2006, Jensen et al. 2008, Heikinheimo et al. 
2010, Marions et al. 2011). Parous women with only Caesarean section 
deliveries also experience more pain (Allen et al. 2014). Studies on 
prophylactic pharmacological pain management, including the use of 
non-steroidal anti-inflammatory drugs (NSAIDs), opioids, nitroprusside, 
lidocaine gel and misoprostol have revealed no evidence supporting 
their routine use, although NSAIDs are considered beneficial in reducing 
post-insertion pain by reducing uterine contractility (Allen et al. 2009, 
Bahamondes et al. 2014, Kaunitz and Nelson 2014). These studies, 
however, have mainly concerned parous women. In the absence of 
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efficient pharmacological pain reduction methods, the importance of 
counselling and verbal anaesthesia is increasingly being emphasized 
(Bahamondes et al. 2014, Kaunitz and Nelson 2014).  
 
Uterine perforation 
 
Mechanical complications with intrauterine contraception are rare. An 
IUD may be fully outside the uterus or adherent, where removal by 
pulling visible threads is unsuccessful. An adherent IUD may be either 
partially perforating with the tail still in utero or embedded in the 
myometrium. In the case of an absent IUD, perforation and an intra-
abdominal location must always be suspected, unless the woman is 
aware of expulsion. Perforation is the least likely option with missing 
strings, after unnoticed expulsion. In most cases the strings have 
retracted and the device is in place (Millen et al. 1978, Marchi et al. 
2012) 
 
Mechanism of perforation 
Two different types of perforation have been proposed, immediate and 
late. In immediate perforation the uterine sound, the inserting tube or the 
IUD pierces the uterine wall at insertion and the IUD is either inserted 
directly into the abdominal cavity or later passes there through the 
iatrogenic opening of the uterine wall (Zakin et al. 1981a&b, Heartwell 
and Schlesselman 1983, Andersson et al. 1998). Proposed reasons for 
late perforation are discrepancy between the size of the IUD and that of 
the uterus, as well as uterine myometrial contractility gradually pushing 
the devices through the myometrium (Goldstuck and Wildemeersch 
2014). Late perforation is supported by cases where the IUD has been 
seen normally positioned in utero prior to diagnosis of perforation (van 
Haudenhoven et al. 2006).  
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Incidence and risk factors 
Both incidence and risk factors have been similar in prospective and 
retrospective studies. Table 4 summarizes results from prospective 
studies. Reported incidences are 0–2.2/1000 insertions with copper 
IUDs and 0.4–2.6/1000 insertions with the LNG-IUS (Andersson et al. 
1998, Caliskan et al. 2003, van Haudenhoven et al. 2006). The post-
partum period and breastfeeding are considered to be major risk factors 
as a result of uterine involution and increased contractility (Andersson et 
al. 1998, Caliskan et al. 2003, van Haudenhoven et al. 2006, van 
Grootheest et al. 2011). In addition to patient characteristics, HCP 
experience in the procedure, as well as an adequate insertion technique 
are crucial, as mentioned above. Perforations have occurred more often 
with inexperienced HCPs inserting fewer than 10 devices annually 
(Zakin et al. 1981a&b, Caliskan et al. 2003, Zhou et al. 2003, Harrison-
Woolrych et al. 2003).  
 
Symptoms, severity, diagnosis and treatment 
The most common findings are abnormal bleeding and lower abdominal 
pain (van Grootheest et al. 2011). Missing threads in asymptomatic 
women (30%) are also a common finding (Gill et al. 2012). Reports of 
severe complications involving intestinal or bladder complications 
caused by a perforating IUD are rare, especially with modern T-shaped 
devices (Zakin et al. 1981a, Gill et al. 2012). Pregnancy may be the only 
reason to suspect misplacement of the device, especially with a copper 
IUD (Sivin and Stern 1979, Zakin et al. 1981a, Andersson et al. 1998). 
If the IUD cannot be seen in vaginal ultrasonography, intra-
abdominal misplacement can be confirmed with an abdominal X-ray. If 
the IUD is not detected in an X-ray, the device has been expelled 
(Boortz et al. 2012). Investigators in large case studies have 
recommended immediate removal in symptomatic cases and in relation 
to IUDs with a closed shape enabling intestinal herniation via the device, 
as these have been related to severe intestinal complications and 
morbidity (Zakin et al. 1981a, Gill et al. 2012). In contrast, the need to 
remove perforating T-shaped devices in asymptomatic cases has been 
questioned in many reports (Zakin et al. 1981b, Adoni and Chetrit 1991, 
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Markovitch et al. 2002, Haimov-Kochman et al 2003a). When treated, 
the procedure of choice is laparoscopy in cases of intra-abdominal 
location or partial perforation (Adoni and Chetrit 1991, Gill et al. 2012). 
Laparotomy can and should be avoided primarily, as the morbidity 
associated with the operation is greater than that in connection with the 
perforation itself in most cases (Adoni and Chetrit 1991, Gill et al. 2012, 
Mosley et al. 2012).  
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Pelvic inflammatory disease and risk of infertility 
 
With increasing popularity of intrauterine contraception in the 1970s, an 
increase in PID and subsequent tubal infertility was observed, especially 
in nulliparous women (Ory 1978, Cramer et al. 1985). Infertility was also 
seen in nulliparous former IUD users with no apparent history of PID, a 
factor later linked to asymptomatic PID (Gareen et al. 2000). 
Conclusions in many studies were to limit the use of IUC in nulliparous 
women. Further studies, however, identified multiple partners and the 
subsequent increased risk of sexually transmitted diseases (STDs) and 
PID in these women as the key risk factor, regardless of parity or age 
(Scott 1978, Osser et al. 1978, Luukkainen et al. 1979, Cramer et al. 
1985, Lee et al. 1988, Struthers 1991). The risk of PID was extensively 
analysed in large studies performed by the WHO and the results 
supported findings in earlier smaller studies. An overall 1.5- to 2-fold risk 
of PID in women using any type of IUD was found compared with 
women using no contraception (Lee et al. 1983, Farley et al. 1992). The 
Dalkon shield differed from other studied devices, with an overall risk 
ratio of 8.4, equally elevated in both nulliparous and parous women. 
However, the elevated risk associated with all other types of devices 
was only present shortly after insertion, except for the Dalkon shield, 
with a 15-fold risk during long-term use (Lee et al. 1983). Although some 
increase in risk was seen in nulliparous women, further grouping 
revealed that this was accounted for by young age and greater risk of 
STDs, and not parity (Farley et al. 1992). In a different cohort a twofold 
risk of PID was also seen in older and parous women in monogamous 
relationships during the first months of use (Lee et al. 1988). Further 
studies by the WHO identified the risk of PID to be increased for only 20 
days post-insertion. 
Conclusions have been that the risk of PID is increased 
shortly after insertion, but lifestyle factors, i.e. multiple partners and the 
related increased risk of STDs affect this risk (Lee et al. 1983, Lee et al. 
1988, Farley et al. 1992). Data on the risk of PID after IUD insertion in 
STD-infected women compared with infected women not having an IUD 
inserted is still inconclusive (Grimes 2000). Pre-insertion counselling and 
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assessing the risk of STDs in all women is therefore recommended at 
insertion. In the event of an STD, this should be treated, but the device 
need not be removed (Caddy et al. 2014). Prophylactic pre-insertion 
antibiotics have not been found useful and are thus not recommended 
(Grimes and Schulz 2001, Caddy et al. 2014).  
Infertility has been linked to the presence of Chlamydia 
trachomatis antibodies, and not to past copper IUD use (Hubacher et al. 
2001). This link was not known in the early 1970s, when the increased 
infertility rates caused concerns (Paavonen 2012). The copper IUD does 
not reduce the risk of PID, as has been the finding with systemic 
hormonal contraception (Senanayake and Kramer 1980) and the LNG-
IUS (Toivonen et al. 1991, Berenson et al. 2013), a factor linked to 
thickening of the cervical mucus forming a barrier between the vagina 
and the uterus. Return to fertility and pregnancy rates after removal of 
copper IUDs (Skjeldestad and Bratt 1987, Bastianelli et al. 1998, 
Mansour et al. 2011) and the LNG-IUS (Bednarek and Jensen 2010, 
Mansour et al. 2011) have been found normal and similar to those in 
women not using contraceptives or using barrier methods only. 
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Continuation of intrauterine contraception 
 
Uterine size 
 
Along with earlier concerns of infertility related to copper and inert 
devices, smaller uterine size in nulligravid/nulliparous women and 
concerns about increased rates of expulsion, bleeding and pain related 
to this still limit the use of IUC in these women. Sound measures in IUD 
studies among nulligravid and nulliparous women have varied between 
5 and 11 cm, with a mean of 7 cm (Suhonen et al. 2004, Brockmeyer et 
al. 2008, Marions et al. 2011) and a similar result, mean 7 cm (6–9 cm) 
was reported in nulligravid adolescents (Bayer et al. 2012). Results in 
parous women are similar, mean 7–7.5 cm (Andersson et al. 1994). 
 Uterine size increases with parity and also so some extent 
age. Table 5 summarizes results from studies using either mechanical or 
imaging techniques to evaluate uterine cavity size. Three of the studies 
summarized in the review compared different measuring techniques in 
the same subjects (mechanical vs. hysteroscopy vs. post-hysterectomy 
measurement, mechanical vs. ultrasonography, and hysteroscopy vs. 
transvaginal vs. transabdominal ultrasonography). The different methods 
showed very similar results (Goldstuck 2012).  
 
 
Table 5. Results from a review summarizing published studies on uterine size. Measurements 
are presented as mm±SD. Goldstuck 2012. 
Measurement  Parity Mechanical measurements* 
Imaging 
measurements* 
Cavity width Nulliparous 25.1 (17.8–32.2) 28.2 (21.0–33.0) 
Multiparous 34.9 (23.4–53.0) 32.1 (26.0–38.0) 
Cavity length Nulliparous 33.7 (18.0–42.1) 37 (-) 
Multiparous 38.6 (20.6–40.3) 44.3 (29.0–64.0) 
* Wing Sound I-II, Cavimeter, Wang device, Batielle caliper, Novasure probe                                ** 
Hysteroscopy, ultrasonography 
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In the few studies on uterine size in women using intrauterine 
contraception, a large proportion of the studied women have had 
measurements smaller than modern devices, regardless of parity (Kurz 
1984, Benacerraf et al. 2010, Canterio et al. 2010). Studies comparing 
uterine size women of different parity are summarized in Table 6. 
 
  
Table 6. Results from studies evaluating uterine size by parity. 
Fundal width (mm, mean±SD) 
Studies Parity Nulligravid Nulliparous 1 2 3 (+) 
Kurz et al. 1984 
n = 795 
    Cavimeter 
23.1±3.1 23.8±3.3 24.5±3.0 25.7±3.5 26.0±2.3 
Benacerraf et al.  
2010, n = 184 
    3-D ultrasonography 
27.1±6.7 28.3±7.5 29.6±6.7 31.1±6.5 (≥2 deliveries) 
Cavity length (mm, mean±SD) 
Studies Parity Nulligravid Nulliparous 1 2 3(+) 
Hasson 1974 
n = 336 
    Wing Sound 
- 29.0 35.0 39.0 40.0 
Kurz et al. 1984 
n = 795 
    Cavimeter 
31.8±4.8 32.2±5.1 33.0±4.8 35.2±5.4 36.9±5.6 
Canteiro et al. 2010  
n = 570    
    2-D ultrasonography - 37.0 38.4 (≥1 deliveries) 
    Sound measure - 38.4 42.5 (≥1 deliveries) 
 
 
The study by Kurz et al., who evaluated uterine size with a mechanical 
device, revealed that the overall cavity length was 33.3±2.0 mm (mean 
±SD) and width 24.6 ± 2.9 mm. The study included women aged 15–44 
years and of differing parity. Both fundal width and cavity length was 
more dependent on parity than age, but no significant correlation 
between either age or parity and size could be demonstrated. The study 
by Hasson revealed an average cavity length of 36 mm, with a clearer 
difference between nulliparous and parous women, but no significant 
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difference between women of different age groups (<20 to >40 years 
old). In the study by Canterio et al. the average cavity length was 
36.8mm ± 6.1, with small differences in ultrasound measurements 
between women of different parity. However, 36% of all participants had 
a cavity length shorter than the studied devices (32 mm and 36 mm), 
regardless of parity. Another study, involving abdominal 
ultrasonography, demonstrated a clear correlation between increasing 
size versus the presence of menarche, adolescence and parity (Gadelha 
Da Costa et al. 2004). When comparing uterine size in adolescents aged 
10–19 (n = 477) with adult women aged 20–40 (n = 351) the authors 
found that nulliparous and primiparous adolescents a had significantly 
smaller uterine volume than older women of similar parity. After two 
pregnancies, age no longer correlated with uterine size. 
 Uterine size also varies with the menstrual cycle, with the 
cavity being smallest at the beginning of the cycle (Hasson 1974, Wang 
1982).  
 
Uterine size and intrauterine contraception 
 
Earlier inert devices relied on large size in relation to the uterine cavity 
for contraceptive efficacy. With the development of smaller devices 
better shaped to fit the uterine cavity, problems with excessive bleeding, 
pain and expulsion have been reduced. High complication rates seen 
with inert devices and prior copper-releasing models are considered a 
consequence of incompatibility between the device and the size of the 
uterine cavity, causing trauma to the endometrium and cramping of the 
uterus (Tejuja 1969, Kamal et al. 1971, Hasson et al. 1976, Goldstuck 
1982, Hubacher 2007, Wildemeersch et al. 2013).  
A normal cavity is considered to be the shape of a triangle. 
However, early studies using hysterography or silicon or rubber molds to 
depict the uterine cavity have demonstrated great variations in the 
shape of the uterine cavity (Hasson 1974, Wang 1982, Goldstuck 2012). 
Expulsions and complications with the Chinese stainless steel ring in 
one large study were related to abnormally shaped uteri, including both 
short, and wide as well as long and narrow cavities and bicornic uteri 
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(Wang 1982). In earlier studies on copper-T IUDs, optimizing both the 
width of the horizontal arm (Hasson 1984, Kurz et al. 1984) and the 
length of the vertical stem (Kaivola 1986) in accordance with 
mechanically taken measurements improved user satisfaction and 
continuation rates. Clinical comparison between the smaller LNG-IUS 
13.5 mg (28 x 30 mm) and the LNG-IUS (32 x 32 mm) across parity 
groups has not demonstrated differences in clinical outcome (Gemzell-
Danielsson et al. 2012), but uterine size was not evaluated.  
Recently, physicians found a significant difference in uterine 
cavity width between women with an embedded or abnormally 
positioned IUD (25 ± 8 mm) and women with normally positioned 
devices (32 ± 10 mm, Shipp et al. 2010). The same group found that 
women with an abnormally positioned IUD were twice as likely to 
complain of bleeding or pain in comparison with those with a normally 
placed IUD, 75% vs. 35% (Benacerraf et al. 2009). Similar studies on 
current models assessing the relationship between uterine length and 
adverse events are not available. However, expulsion does not seem to 
be related to short uterine length (Bahamondes et al. 2011a).  
Opinions on whether or not smaller devices are needed 
differ. Concerns have also led to the development of the frameless 
copper device, but results in studies have not proven its superiority over 
the framed TCu380 models currently most used (O’Brien and Maarfleet 
2006). In earlier studies on different models of copper devices the 
majority have revealed better performance with smaller devices in 
nulliparous women (Hubacher 2007). During the last decade the 
TCu380 has been recommended as the copper device of choice, as it 
has been found to have the best clinical and contraceptive performance 
(O’Brien et al. 2008). Recent studies mainly concern this device and the 
LNG-IUS, all with good outcome in both nulliparous and parous women 
(Lete et al. 1998, Brockmeyer et al. 2008, Bahamondes et al. 2011b, 
McNicholas et al. 2012, Berenson et al. 2013, Aoun et al. 2014).   
 35	  
Expulsion 
 
When comparing different copper devices, many trials have revealed 
smaller expulsion rates with smaller devices, but the data is inconsistent. 
Expulsion rates range from 1.8–12.7% at 12 months and 2.5–13% at 24 
months with models of different sizes and shapes (Hubacher 2007). 
Similarly, when comparing the same differently sized and shaped 
devices between women of different parity, most trials have revealed 
more expulsions in nulliparous women compared with parous women. 
Only with the currently used TCu380 models have rates been similar or 
lower in nulliparous women, 3.3% to 6.2% (Hubacher 2007).   
With the LNG-IUS, expulsion rates have been similar or 
lower in nulligravid/nulliparous women in comparison with parous 
women. One year rates are 1–6% (Suhonen et al. 2004, Bahamondes et 
al. 2011b, Marions et al. 2011, Madden et al. 2014) in comparison with 
2–8% in parous women (Jensen et al. 2008, Bahamondes et al. 2011b, 
Aoun et al. 2014). At three years the cumulative rates of expulsion have 
also been similar or lower in nulligravid/nulliparous women, 6.7%–6.9% 
vs. 5.8%–12.2% in parous women (Behringer et al. 2011, Madden et al. 
2014). Recent studies have compared the LNG-IUS against the 4-mm-
longer TCu380A used in the U.S. Expulsion rates with the copper device 
have been twofold in comparison with the LNG-IUS, not differing with 
parity (Bahamondes et al. 2011a, Aoun et al. 2014, Madden et al. 2014).   
 
When comparing adolescents (aged ≤ 20 years) with adult women (aged 
> 20 years) of similar parity, results differ between studies. With both the 
TCu380A and the LNG-IUS, both similar rates (Aoun et al. 2014) and 
doubled rates of expulsion (Behringer et al. 2011, Madden et al. 2014) 
have been reported in adolescents.   
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Continuation rates and reasons for discontinuation in 
nulligravid/nulliparous and young women 
 
Continuation rates at one and two years with current copper devices and 
the LNG-IUS are superior to those connected with all short acting 
contraceptive methods, regardless of parity and age (WHO 2010, 
OʼNeil-Callahan 2013; Table 2). Age affects continuation rates with all 
contraceptives, as younger women tend to discontinue more often as a 
result of a desire for pregnancy, but also because of adverse events 
and, especially in the youngest group, financial problems. Adolescents 
are twice as likely as adult women to discontinue any form of 
contraception (O’Neil-Callahan 2013). Although this age group also 
discontinues LARC methods more often than adult women, the 
difference seen between the discontinuation rates with LARC methods is 
small between age groups (McNicholas et al. 2014). 
Studies carried out to evaluate continuation rates in 
nulliparous women using the LNG-IUS include a large proportion of 
nulligravid women. Continuation rates at one year in these women are 
similar or superior to those in parous women, 80–93% (Suhonen et al. 
2004, Jensen et al. 2008, Bahamondes et al. 2011b, Behringer et al. 
2011). When dividing nulligravid/nulliparous adult women by age and 
comparing women of < 25 years of age with older women, the findings 
remain the same (Marions et al. 2011). In a long-term study on parous 
women using the NovaT IUD (32 x 32 mm) or the LNG-IUS (32 x 32 
mm), the only difference between age groups was higher removal rates 
because of a desire for pregnancy in women younger than 30 years of 
age (Andersson et al. 1994), but continuation rates were similar with 
both devices (Andersson et al. 1994, Sivin and Stern 1994). 
Comparative studies with the TCu380A (32 x 36 mm) used in the U.S. 
and the LNG-IUS, including nulligravid/nulliparous and parous women, 
indicate continuation rates overall are somewhat lower with the copper 
device, but similar across parity groups (Berenson et al. 2013, Aoun et 
al. 2014). In the study by Aoun et al. (2014), nulliparous women reported 
more dysmenorrhoea, but continuation rates were not affected. Other 
copper devices have not been compared with the LNG-IUS in large 
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studies. Continuation rates in adolescents (aged ≤ 20 years) using the 
LNG-IUS do not differ from those in adult women (Behringer et al. 2011, 
Marions et al. 2011, Berenson et al. 2013). However, comparative 
studies with TCu380 models and the LNG-IUS have revealed higher 
rates of discontinuation with the copper device in adolescents, mainly 
because of pain (Rosenstock et al. 2012, Berenson et al. 2013, Aoun et 
al. 2014). Discontinuation as a result of bleeding disturbances does not 
differ between parity or age groups with either type of device (Andersson 
et al. 1994, Bahamondes et al. 2011b, Behringer et al. 2011, Berenson 
et al. 2013, Aoun et al. 2014), with 1–5% requesting removal for this 
reason (Bahamondes et al. 2011b, Behringer et al. 2011), although the 
proportion reporting changes or disturbances in menstruation is 
significantly greater in all women using IUC. 
The contraceptive efficacy of the NovaT has been 
compared with that of the LNG-IUS only in parous women, the results 
being similar with both devices (Sivin and Stern 1994). In contrast, the 
efficacy of the TCu380A used in the U.S. has been somewhat lower 
than that of the LNG-IUS across all age groups and parities in adult 
women, although pregnancy rates with both devices are low (Berenson 
et al. 2013, Aoun et al. 2014, NcNicholas et al. 2014, Heinemann et al. 
2015). Most studies indicate comparable contraceptive efficacy of both 
types of IUC in adolescents and adult women, but the study by 
Berenson et al. (2013), including 90 000 women, revealed a significantly 
higher risk for pregnancy with both devices in adolescents compared 
with women aged ≥ 25 years (OR 1.42 1.13–1.79), but not compared 
with women aged 20–24 years.  
 38	  
Current guidelines 
 
With positive results on safety and user satisfaction associated with 
modern IUC, as well as excellent contraceptive efficacy, current 
guidelines strive to promote its use globally, and especially in young and 
nullligravid/nulliparous women. The medical eligibility criteria for 
contraceptive use, published in 2010 by the WHO, cautiously 
recommend IUC for both women under the age of 20 and adult 
nulligravid/nulliparous women (category 2/4 = generally use the 
method), stating that data on the risk of infertility remains conflicting, but 
evidence supporting the safety of IUD use in these women is increasing 
(WHO 2010). Newer national guidelines recommend LARC, including 
intrauterine contraception, as first-line contraception in both adolescents 
and nulligravid/nulliparous women (ACOG 2012, CDC 2013, NICE 
2014). Finland currently has no national guideline on contraceptive use, 
but the Finnish National Institute for Health and Welfare (THL) 
recommends IUC to be promoted among nulligravid/nulliparous women 
(THL2014c).  
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6. AIMS OF THE STUDY 	  
 
The aims of the prospective study on nulligravid women were: 
 
• To assess IUD insertion in nulligravid women and to identify 
factors related to difficulties at IUD insertion.  
 
• To assess bleeding, pain and user satisfaction among nulligravid 
women during the first year of use with the LNG-IUS or a copper-
releasing IUD (NovaT®, TCu380Ag). 
 
• To assess the potential effects of uterine size, evaluated by 
ultrasonography, on IUD insertion and long-term use. 
 
 
 
The aims of the registry-based study were: 	  
• To examine the incidence of and factors associated with uterine 
perforation in connection with IUD use in Finland.  	  
• To evaluate the clinical course and findings at surgery among 
women treated for IUD perforation. 
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7. SUBJECTS AND METHODS  
 
Prospective study on nulligravid women and uterine size 
 
The study was carried out at the Centralized Family Planning of the City 
of Helsinki. Women who contact the clinic with a request for 
contraception are counselled by trained midwives. Nulligravid women 
aged 18 or above requesting their first IUD after contraceptive 
counselling, either the LNG-IUS or a copper-releasing device, were 
invited to join the study. Inclusion and exclusion criteria are shown below 
(Table 7).  
 
 
Table 7. Inclusion and exclusion criteria in the study on nulligravid women. 
Inclusion criteria Exclusion criteria 
Age ≥ 18 years Known structural uterine abnormality 
Resident of Helsinki Submucous or intramural fibroid  
No prior pregnancies  Acute gynaecological infection 
No contraindication to IUD use 
Understands Finnish or Swedish  
      (language in diaries) 
Suspicion of gynaecological malignancy 
In addition, with the copper-releasing IUD: 
      Bleeding disorder 
      Heavy bleeding causing anaemia 
      Anaemia 
      Wilson’s disease 
      Allergy to copper or nickel 
  
 
Between January 1st, 2011 and July 31st, 2012 we enrolled 165 women. 
The women were given a free choice between the devices used in the 
study, the LNG-IUS (Mirena®) and the copper-releasing device NovaT® 
(TCu380Ag). Both devices are T-shaped, have frames of equal size and 
measure 32 x 32mm. The inserting tubes of the devices, however, differ 
in size as the hormonal cylinder of the LNG-IUS makes its vertical arm 
slightly wider. The traditional LNG-IUS inserter has an outer diameter of 
4.75 mm and the newer inserter a diameter of 4.40 mm. As the new 
inserter was introduced during the study period, both were used 
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according to availability. Any possible effect on insertion of the differing 
size of the inserters was tested before proceeding with analyses. The 
insertion tube of the copper IUD has an outer diameter of 3.65 mm. 
One experienced gynaecologist (SS) treated all the women, 
and interviewed them as regards demographic and menstrual 
characteristics prior to insertion. Women using hormonal contraception 
at the time were asked to report details of their spontaneous 
menstruation. They reported the amount of bleeding on a Likert scale of 
none, spotting, scanty, normal and heavy. In analyses, the first three 
categories were combined into one group, as women reporting no 
bleeding or spotting in spontaneous cycles were few. Similarly, the 
women reported menstrual pain as none, minimal, disturbing and 
severe.  In analyses, the categories none and minimal were combined 
into one group, as only a few women reported no pain. Disturbing and 
severe menstrual pain was analysed both separately and as one group 
of dysmenorrhoea against the group of none to minimal pain. Table 8 
summarizes subject characteristics.  
The women were asked to take the equivalent of 800 mg of 
ibuprofen or 1000 mg of paracetamol one hour prior to the insertion, as 
is standard practice at the clinic, and to empty their bladders. 
Immediately before insertion, the gynaecologist measured the uterus 
using vaginal 2-D ultrasonography and carried out a clinical pelvic 
examination including measurement of uterine depth with a metallic 
sound. Uterine cavity length and cervical length were measured 
separately in a sagittal plane and summed to calculate total uterine 
length. Fundal width was measured at the widest possible point in a 
transverse plane. The uterine flexion angle was calculated as the angle 
between the cavity and the line of cervical length measurements (Figure 
2). As uterine position (ante- vs. retroversion) was insignificant in 
analysis of insertion pain and difficulties, flexion angle was coded as 
ranging from 0 to 180 degrees, with 180 degrees being a straight uterus.   
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Table 8. Characteristics of the studied nulligravid women. Data are presented as median (range) 
unless otherwise specified. 
 All women (n=165) 
LNG-IUS 
(n=113, 68.5%) 
Copper IUD 
(n=52, 31.5%) p-value 
Age (years) 24.0 (18-43) 23.0 (18-43) 25.0 (19-37) 0.03 
 Agegroups n (%)   <20 11 (6.7) 9 (8.0) 2 (3.8) 
NS                                  20-24 79 (47.9) 60 (53.1) 19 (36.5)                                  25-35 68 (41.2) 39 (34.5) 29 (55.8) 
                                 >35 7 (4.2) 5 (4.4) 2 (3.8) 
BMI (kg/m2) 23.3 (16.9-55.2) 
22.3 
(16.9-42.6) 
22.6 
(17.7-55.2) NS 
Smoking n (%) 40 (24.2) 30 (26.5) 10 (19.2) NS 
Dyspareunia n (%) 28 (17.0) 21 (18.5) 7 (13.5) NS 
Dyschezia n (%) 39 (18.2) 22 (19.4) 8 (15.4) NS 
Abdominal pain other than menstrual n (%) 
 70 (42.4) 52 (46.0) 18 (34.6) NS 
Age at menarche 12.0 (8-17) 12.0 (8-17) 13.0 (9-16) NS 
Reported spontaneous bleeding n (%) 
Amenorrhoea 1 (0.6) 1 (0.9) 0 (-) 
<0.001 Spotting or scanty 20 (12.1) 13 (11.5) 7 (13.5) Normal 98 (59.3) 58 (51.3) 40 (76.9) 
Heavy 46 (27.9) 41 (36.3) 5 (9.6) 
Days with bleeding 5 (0-39) 5 (0-39) 5 (3-8) NS 
Cycle length 28 (21-135) 28 (21-135) 28 (21-80) NS 
Reported menstrual pain n (%) 
None or minimal 84 (50.9) 48 (42.8) 36 (69.2) 
0.001 Dysmenorrhoea 50 (30.3) 36 (31.9) 14 (26.9) 
Severe dysmenorrhoea 31 (18.8) 29 (25.7) 2 (3.8) 
Days with menstrual pain 1.75 (0-7) 2 (0-7) 1 (0-4) 0.01 
Need for analgesics at time of menses n (%) 
 102 (61.8) 81 (71.7) 21 (40.4) <0.001 
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Figure 2. Cavity length (A) and cervical length (B) were measured separately 
in a sagittal plane (left) and summed to calculate total uterine length (A+B). 
The flexion angle (C) was calculated by measuring the angle between the lines 
of the length measurements (A+B) in the sagittal plane. Fundal width (D), here 
demonstrated in an antero-posterior view, was measured at the widest point in 
a transverse plane. 
 
Immediately after insertion the correct location of the IUD was checked 
ultrasonographically. Both the woman and the gynaecologist evaluated 
insertion pain on a Likert scale of none, mild, moderate, severe and 
intolerable. In addition, the gynaecologist evaluated the insertion by 
classifying the procedure as easy, difficult or failed and assessing the 
reason for a possible failed insertion. Cervical traction to straighten the 
uterus and the need of dilatation was recorded, as was the possible 
need of paracervical block (PCB) or use of misoprostol to soften the 
cervix. Only the use of metallic Hegar dilators was considered to be 
dilatation. PCB (lidocaine, 10 mg/mL) and sublingual misoprostol (0.4 
mg) were used only in cases where pain or cervical tightness would 
have prevented the insertion.  
After insertion women kept daily diaries on bleeding, pain 
and use of pain medication during two separate reference periods of 90 
days. The 1st reference period started at the day of insertion (months 1–
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3). The 2nd reference period comprised the last 90 days of the first year 
of IUD use (months 10–12). The women noted days with bleeding and 
days with spotting. In cases of lower abdominal pain, the women 
assessed the intensity as mild, equal to menstrual pain or exceeding 
menstrual pain.  
All women were scheduled for two follow-up visits, the first 
one at three months and the second one at one year after insertion. 
They were asked to return their diaries at the visits. In addition, the 
women were asked to contact the clinic between scheduled visits if 
needed and in the case of a desire to discontinue IUD use. The first visit 
was primarily with a midwife, who interviewed the woman and checked 
the IUD threads. In cases of difficult insertion, difficulties during the first 
three months or missing threads, the gynaecologist examined the 
woman by means of vaginal ultrasonography. The one-year visit was to 
the gynaecologist performing insertions.  
Diaries were analysed according to WHO recommendations 
(Belsey et al. 1986). Numbers of days of bleeding and spotting days in 
each reference period were counted separately as well as together. In 
addition, each month was studied separately. Numbers of episodes of 
bleeding and spotting and length of the episodes, cycles and 
bleeding/spotting-free intervals were noted and thus bleeding patterns 
could be assessed. One bleeding/spotting-free day was considered to 
belong to the episode surrounding it. Prolonged bleeding was defined as 
bleeding/spotting episodes lasting more than 14 days, frequent bleeding 
as more than five episodes per reference period and infrequent bleeding 
as 1–2 episodes per reference period. Results from diaries were also 
compared with the uterine measurements taken prior to insertion and 
with menstrual characteristics reported by the women. 
Ethics 
The Ethics Committee of the Hospital District of Helsinki and Uusimaa 
gave a positive statement (n:o 149/13/03/03/2010) as did the City of 
Helsinki Health Center (n:o 10-1137/054), and the study was registered 
at www.clinicaltrials.gov (NCT01685164).  
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Statistical analysis  
Statistical analysis was carried out using SPSS Statistics Software 21.0 
(IBM, New York, USA). Statistical significance was defined as p < 0.05. 
Chi-square and Fisher’s exact tests were used to compare categorial 
variables and the Mann–Whitney U test was similarly used for 
continuous variables. Uterine measurements were initially analysed as 
continuous variables and tested against different parameters to find 
correlations. Measurements were then grouped by medians, quartiles 
and quintiles. In quartile and quintile analysis, groups were created by 
dividing uterine measurements into equally wide groups, not by making 
groups by number of women.  
When seeking predictive size measurements, flexion angle 
and patient characteristics in relation to difficulties at IUD insertion, 
binominal and multiple regression were used. When searching for 
threshold measurements predicting insertion difficulties (easy vs. 
difficult-failed insertion) the Receiver Operating Characteristic (ROC) 
curves were used. For each measurement variable, different point 
estimates suggested on the curve were tested against difficulties at 
insertion to determine possible threshold measurements. Initial analyses 
were carried out separately by type of device and type of inserting tube 
used at insertion of the LNG-IUS, but as no significance was found in 
difficulty of insertion, the women were analysed as one group and type 
of IUD was used as a confounding variable. 
Correlation between uterine measurements and bleeding, 
spotting and reported pain during follow-up was analysed by using 
Spearman’s correlation. When analysing diary data, linear regression 
was used to find predictive models for continuous variables and binomial 
logistic regression similarly for categorial variables. After grouping 
measurements by medians, quartiles or quintiles, the Mann–Whitney U 
test was used to compare results between the IUD groups, as well as 
when analysing differences between bleeding and pain within each IUD 
group.   
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Registry-based study on uterine perforation 
 
Women surgically treated for uterine perforation were identified from the 
nationwide Hospital Discharge Register by combining ICD-10 
(International Classification of Diseases, 2010) and the operation codes 
of the Nordic Medico-Statistical Committee (NOMESCO 2010) 
Classification of Surgical Procedures (Table 9). There is currently no 
specific code for perforation caused by an IUD. 
 
 
Table 9. Codes used to identify patients treated for uterine perforation associated with IUD use. 
ICD-10 code Operative code 
T83.3 Mechanical complication by an IUD JAL-10 Laparotomy and removal of 
foreign body 
T19.3 Intrauterine foreign body JAL-11 Laparoscopy and removal of 
foreign body 
Z30.1 
Z30.5 
IUD insertion- and follow-up related 
codes 
JAL-20 Removal of foreign body from the 
uterus 
  JAL-22 Hysteroscopic removal of foreign 
body 
 
 
The study period was 15 years, starting on January 1st 1996, when ICD-
10 was introduced in Finland, and ending on December 31st 2009. 
Hospital records were examined to assess patient characteristics, 
insertion-related data, pre-diagnostic symptoms and findings in surgery. 
As only records from the Hospital District of Helsinki and Uusimaa  could 
be retrieved, the study was limited to women treated in this area. In the 
incidence calculations only cases with time of insertion falling inside the 
study period were included in order to exclude the possibility of some 
patients having been treated prior to the study and thus falsely lowering 
the incidence prior to 1996. When assessing the clinical course of the 
patients, only cases where the type of device could be defined were 
analysed. Figure 3 shows the study flowchart.  
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Figure 3. Flowchart of IUD-related uterine perforation studies.  
 
Clinical course and  
treatment study 
3909 patients 
identified from the Hospital Discharge Register 
370 suspected IUD related uterine perforations 
108 women (29%)  
treated in the Helsinki and Uusimaa area 
3539 excluded:  
combined codes, male patients 
262 excluded: treated in other parts 
of the country 
30 excluded: IUD-related treatment 
other than perforation 
78 perforations 
Incidence study 
10 excluded: insertion 
prior to the study period 
68 analysed 
3 excluded: type of 
device undetermined 
75 analysed 
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The incidence of uterine perforation with an IUD was calculated by using 
sales figures provided by the pharmaceutical company marketing the 
LNG-IUS and the NovaT (Bayer AG, Berlin, Germany). The two devices 
account for more than 95% of all nationwide sold IUDs during the study 
period. Sales figures for a copper IUD marketed by another company 
could not be retrieved. As only patients treated within the Helsinki and 
Uusimaa area could be analysed, incidence was calculated using sales 
figures from this area. Devices sold in this area account for 29% of 
devices sold nationwide, as did the proportion of women identified from 
the nationwide register. Precise sales figures by geographical area are 
available for the LNG-IUS from 1997 and for copper-releasing devices 
from 2004. Numbers prior to this were estimated as 33% of devices sold 
nationwide annually for the LNG-IUS and 25% for the copper-releasing 
device according to recent precise geographical sales figures. The LNG-
IUS has accounted for the great majority of sold devices in recent years 
(80–88%). 
By analysing hospital records, data on patient 
characteristics, insertion, pre-diagnostic symptoms, clinical course and 
operative findings could be assessed. Patient characteristics are shown 
in Table 10. 
Ethics 
The Ethics Committee of the Hospital District of Helsinki gave the study 
a positive statement (n:o 51/13/03/03/2010) and the study was approved 
by the hospital. The Ministry of Social Affairs and Health (STM) and the 
National Institute for Health and Welfare (THL) gave their approval to 
use the registry data (n:o STM/1771/2010). 
Statistical analysis 
Statistical analysis was carried out using SPSS Statistics Software 18.0 
(IBM, New York, USA). Statistical significance was defined as p < 0.05. 
The retrospective nature and lack of a control group limited analyses to 
a descriptive nature. The Mann–Whitney U test, Chi-square tests and 
Fisher’s exact test were used to analyse and compare LNG-IUS users 
with women using copper IUDs. 	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Table 10. Selected demographic characteristics of women with surgically removed perforating or 
embedded IUDs. The data is presented as n (%) unless stated otherwise. 
n = 75  LNG-IUS n = 54 Copper IUD n = 21 * 
Age (years) Median (range) 34 (20-65) 35 (24-47) 
BMI (kg/m2) Median (range) 23.2(17.9-39.6) 22.8 (19.7-36.5) 
Parity Nulliparous 1 (2) 0 
Parous 53 (98) 21 (100) 
Prior vaginal delivery 48 (89) 17 (81) 
Delivery within 12 months  33 (61) 15 (71) 
missing n = 2 (3) 0-3 months 9 (17) 6 (28.5) 
 3-6 months 17 (31.5) 6 (28.5) 
 6-12months 7 (13) 3 (14) 
 No recent delivery 20 (37) 5 (24) 
Breastfeeding at time of insertion    
missing n = 29 (39) Yes 13 (24) 9 (43) 
No 20 (37) 4 (19) 
Amenorrhoea at time of insertion    
missing n = 43 (57) Yes 13 (24) 11 (52) 
No 8 (15) - 
Prior abdominal or gynaecological surgery  29 (54) 14 (67) 
 Endometriosis  3 (6) 1 (5) 
 Salpingectomy  
(ectopic pregnancy) 0 2 (10) 
 Curettage 13 (24) 8 (38) 
 • 1 procedure 5/13 (38) 2/8 (25) 
 Leep treatment 5 (9) - 
 Intestinal surgery 4 (7) 3 (14) 
*Fincoid 1, FlexiT 1, NovaT380Ag 13, unspecified type of Cu-IUD 6 
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8. RESULTS 
 
STUDY ON NULLIGRAVID WOMEN 
 
Type of IUD chosen 
The majority, 113 women (68.5%), chose the LNG-IUS, while 52 women 
(31.5%) chose the copper IUD. Self-reported heavy menstrual bleeding 
(OR 7.02, 95% CI 2.32–21.18, p = 0.001) and dysmenorrhoea (OR 3.21, 
95% CI 1.58–6.55, p = 0.001) affected choice towards the LNG-IUS. In 
particular, women with severe dysmenorrhoea chose the LNG-IUS (OR 
14.00, 95% CI 2.37–82.72, p = 0.004).  
 
Uterine measurements 
Size measurements are shown in Figure 4 and flexion angles in Figure 
5. As the quality of the ultrasonographic pictures was poor in four cases, 
161 cases could be assessed. Measurements were small compared with 
the measurements of the IUDs. Cavity length was shorter than 32 mm in 
53 women (32.9%) and fundal width smaller than 32 mm in 158 women 
(98.1%). The sound measure was 11.7 ± 7.9 mm (mean ± SD) longer 
than total uterine length measured by ultrasonography. Flexion angles 
ranged from 61 to 173 degrees, with a median of 121.5 degrees.  
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Figure 4. Uterine dimensions as measured by ultrasonography and sound 
measurement (median, 25th and 75th percentiles and min/max). Cavity area is 
presented as cm2, other measurements as millimetres (mm). 	  	  
	  
 
Figure 5. Distribution of flexion angles. Median 121.5, range 61–173. The 
angle of a straight uterus is 180 degrees. 
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Insertion and effect of uterine size on insertion difficulties 
Most insertions (n=147, 89.1%) were classified as easy, 86.7% (98/113) 
in the LNG-IUS group and 94.2% (49/52) in the copper IUD group 
(p=0.30). The type of inserting tube used in connection with the LNG-
IUS was an insignificant factor. In addition to the standard metallic 
sound, a smaller silicone sound was needed to explore the cervical 
canal prior to insertion in 11 of these cases (6.8%)  
Of the 15 (9.1%) difficult insertions, 13 (11.7%) occurred in 
the LNG-IUS group and two (3.9%) in the copper IUD group. Five 
difficult insertions required no additional cervical procedures. Metallic 
Hegar dilators were used in ten cases (6.2%), combined with PCB in six 
cases (3.7%) where pain would have prevented insertion otherwise. 
Misoprostol was used in combination with Hegar dilatation in three 
difficult cases (1.9%) with cervical stenosis.  
Three insertions failed (1.8%); one because of pain (copper 
IUD), one because of a bicornic uterus preventing the IUD fitting 
properly (LNG-IUS), and one insertion was cancelled because of a 
hypoplastic uterus (LNG-IUS, total uterine length by ultrasonography 42 
mm and sound measure 45 mm).  
 Analysis suggested a correlation between difficult insertion 
and small length measurements and flexion angles (Table 11). Uterine 
position (ante- vs. retroversion) and subject characteristics were 
insignificant.   
 
 
 
  
Table 11. Measurements by ease of insertion (median). 
Measurement  Easy Difficult/failed p-value 
Total uterine length (mm) 65.2 57.4 0.02 
Cavity length (mm) 35.4 32.2 0.09 
Cervical length (mm) 29.3 26.0 0.23 
Fundal width (mm) 22.8 24.1 0.97 
Uterine cavity area (cm2) 39.6 38.4 0.82 
Flexion angle (degrees) 123 106 0.006 
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With every increasing millimetre in total length (OR 0.86, 95% CI 0.78–
0.96, p = 0.006) and increasing degree of flexion angle (OR 0.96, 95% 
CI 0.93–0.99, p = 0.004) the odds of a difficult insertion decreased. 
Cavity and cervical length were not significant separately. 
When grouping the women by uterine size, a total uterine 
length smaller than the median (64.4 mm) was associated with a difficult 
insertion (OR 3.63, 95% CI 1.13–11.67, p = 0.03), both independently 
and when adjusting by type of IUD, absence of bleeding at insertion and 
patient characteristics shown in Table 10 (OR 5.59, 95% CI 1.01–28.89, 
p = 0.04). This was also seen as regrads flexion angle (univariate 
analysis OR 5.36, 95% CI 1.48–19.47, p = 0.01 and multivariate 
analysis OR 5.82, 95% CI 1.54–21.98, p = 0.009). Grouping by quartiles 
of size did not reveal significant information.  No predictive threshold 
measurements were found using the ROC curve, as the best point 
estimate predicted only 19–23% of difficult insertions for each 
measurement. 
 
Insertion pain 
Eighteen women (11.2%) reported mild pain, 49 women (30.4%) 
moderate pain, 91 women (56.5%) severe pain and three women (1.9%) 
intolerable pain. The physician commonly assessed pain as one step 
milder than did the woman undergoing insertion (p < 0.001). The 
absence of bleeding during insertion did not correlate with ease of 
insertion or pain experience. There was no difference in pain perception 
sa regards the two LNG-IUS insertion tubes. Women who had the 
copper IUD inserted experienced less severe pain and none 
experienced intolerable pain in comparison with women fitted with a 
LNG-IUS (OR 0.45, 95% CI 0.23–0.89, p = 0.02). However, when 
adjusted by level of menstrual pain this difference became insignificant 
(OR 0.6, 95% CI 0.29–1.22, p = 0.16). In univariate analysis only, every 
increasing millimetre in fundal width and cm2 in cavity area decreased 
the odds of severe or intolerable pain, as did total length exceeding the 
median measurement. Other uterine size measurements were 
insignificant, as was multivariate analysis of all uterine measurements. 
Severe dysmenorrhoea was the only predictor of severe/intolerable 
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insertion pain and the odds ratio increased in multivariate analysis 
(Table 12).  
 
 
Table 12. Odds of severe (n=91, 56.5%) and intolerable (n=3, 1.9%) insertion pain grouped by 
self-reported level of menstrual pain in spontaneous cycles. 
Menstrual pain 
Univariate analysis* Multivariate analysis** 
n (%) OR (95% CI) p-value OR (95% CI) p-value 
None/mild  83 (51.6) reference - reference - 
Dysmenorrhoea  48 (29.8) 1.4 (0.7-2.9) 0.32 1.9 (0.9-4.0) 0.12 
Severe 
dysmenorrhoea 30 (18.6) 5.1 (1.8-14.7) 0.002 7.9 (2.5-24.9) <0.001 
* p = 0.009  
** p = 0.002      
 
 
Continuation rates and adverse events  
The women were generally satisfied during follow-up. The study 
flowchart (Figure 6) shows continuation rates and Table 13 shows 
adverse events leading to IUD removal. The first diary was returned by 
134 women (82.7% of the 162 women with a successful insertion), the 
second by 102 women (87.9% of the 116 women still using the IUD at 
one year) and both by 96 women (82.7% of the 116 women still using 
the IUD at one year). 
 
 
Table 13. Adverse events causing discontinuation n (%).  
 LNG-IUS n = 10/93 (10.8%) Copper IUD n = 7/42 (16.7%)  
Expulsion 3 (3.2) 2 (4.8) 
Bleeding / pain 4 (4.3) 4 (9.5) 
Acne 2 (2.2) 0 (-) 
Premenstrual symptoms 1 (1.0) 1 (2.4) 
p-values NS.   
 
 
Women discontinuing because of expulsion or disturbing bleeding or 
pain had similar uterine measurements as those continuing IUD use. In 
univariate analyses, expulsion was associated with difficult insertion (OR 
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6.7, 95 % CI 1.1–41.8, p = 0.04), obesity (BMI > 30 kg/m2, OR 15.3, 
95% CI 2.6–88.0, p = 0.002) and dyspareunia before IUD insertion (OR 
6.22, 95% CI 1.6–33.3, p = 0.03). In multivariate analysis only obesity 
persisted as a factor predicting expulsion (OR 10.0, 95% CI 1.5–67.1, p 
= 0.02).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Flowchart of study participants. LNG-IUS = levonorgestrel-releasing 
intrauterine system, Copper IUD= copper-releasing intrauterine device, NovaT. 
  
165 nulligravid women 
113 LNG-IUS 52 Copper IUD 
111 insertions 51 insertions 
IUD removals 
10 adverse events (10.8%) 
2 desire for pregnancy 
Lost to follow-up 
18 (16.2%) 
IUD removals 
7 adverse events (16.7%) 
Lost to follow-up 
9 (17.6%) 
Continued IUD use at 1 year  
116/162  (71.6%) 
1 cancelled 2 cancelled 
Still using IUD at 1 year  
81/111 (73.0%) 
 
Still using IUD at 1 year  
35/51 (68.6%) 	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Results from diaries concerning bleeding and pain 
With both devices a high number of bleeding/spotting days occurred 
during the first month, but thereafter a rapid decrease was seen. 
Bleeding/spotting stabilized after the first month among copper IUD 
users, while it continued to decrease month by month among LNG-IUS 
users (Figure 7). There was no statistically significant difference in the 
median number of bleeding/spotting days between the two groups in the 
1st reference period (months 1–3, p = 0.21). 
 
 
 
Figure 7. Median numbers of bleeding/spotting days per month with 25th and 
75th percentiles.   
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By the 2nd reference period both bleeding and spotting days had 
decreased significantly among LNG-IUS users in comparison with 
copper IUD users (median decrease 28 vs. 10 days respectively, p < 
0.001). Amenorrhoea and spotting-only was common among LNG-IUS 
users, while all copper IUD users experienced bleeding days throughout 
the study period (Table 14).  
 
 
Table 14. Proportion of women (%) with bleeding patterns classified by WHO criteria. 
Bleeding pattern 
Reference period 
LNG-IUS 
months 1-3 
LNG-IUS 
months 10-12 
Copper IUD 
months 1-3 
Copper IUD 
months 10-12 
Regular bleeding 8.8 27.0 23.2 64.2 
Amenorrhoea 0 25.7 0 0 
Spotting only 1.1 14.9 0 0 
Infrequent bleeding 14.3 23.0 2.3 0 
Prolonged bleeding 57.1 1.4 27.9 7.1 
Frequent bleeding 14.3 4.1 27.9 14.3 
 
 
During the first month after insertion the total number of days with pain 
was similar in both groups; median 12 among LNG-IUS users and 11.5 
among copper IUD users. As seen with bleeding/spotting, pain stabilized 
after the first month in copper IUD users (to 4-6 days), while continuing 
to decrease to a monthly median of 0–1 before the 2nd reference period 
among LNG-IUS users. In the 1st reference period there was no 
difference in reported number of days with pain between groups. In the 
2nd reference period copper IUD users reported more pain than LNG-
IUS users (p <0.001).   
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Impact of subject characteristics on bleeding and pain 
Spontaneous bleeding affected bleeding with the LNG-IUS, but not with 
the copper IUD. LNG-IUS users reporting scanty spontaneous bleeding 
had fewer bleeding/spotting days throughout the study in comparison 
with those reporting normal or heavy bleeding; median 13 vs. 37 and 
38.5 days, respectively in the 1st reference period (p = 0.02), and 
respectively, median 0 vs. 10.5 and 10.5 days in the 2nd reference 
period (p = 0.03). Scanty bleeding predicted amenorrhoea in the 2nd 
reference period both independently (OR 7.93, 95% CI 1.73–36.46, 
p=0.008) and when tested against uterine measurements (OR 8.17, 
95% CI 1.38–48.21, p = 0.02). Similarly smoking predicted amenorrhoea 
both independently (OR 3.60, 95% CI 1.18–11.00, p = 0.03) and when 
tested against bleeding characteristics and uterine measurements (OR 
8.23, 95% CI 1.76–38.56, p = 0.007). 
Menstrual pain prior to IUD insertion correlated with 
reported pain during IUD use. During the 1st reference period LNG-IUS 
users with no or mild menstrual pain reported less pain (median 14 
days) in comparison to women with dysmenorrhoea (median 20.5 days), 
and particularly severe dysmenorrhoea (median 34.5 days, p < 0.001). 
This was also seen in the 2nd reference period (median 1 vs. 6.5 and 9.0 
days, respectively, p = 0.02).  
Among women using the copper IUD, a similar difference 
between different categories of menstrual pain was seen in the 1st 
reference period (median 20 vs. 35 and 45 days, p = 0.01). During the 
2nd reference period there was no difference in reported number of total 
days with pain (median 17–18 days). However, the only two women with 
severe dysmenorrhoea had discontinued the study (pain, lost to follow-
up). 
A painful or difficult insertion was not associated with pain 
during IUD use.   
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Uterine size and bleeding 
Among LNG-IUS users, increasing size measurements correlated with 
more bleeding/spotting and spotting-only days in both reference periods. 
As this association was not found for bleeding-only days, the 
significance can be assumed to concern spotting primarily. Increasing 
total uterine length (correlation coefficients r = 0.27 and 0.28, p = 0.01), 
cavity length (r = 0.29 and 0.32, p = 0.01) and cavity area (r = 0.22 and 
0.33, p < 0.001) correlated with more bleeding/spotting days in the 1st 
reference period. This was confirmed when grouping women by uterine 
size (Figure 8). In both median and quartile analysis, fewer 
bleeding/spotting days were seen with smaller measurements. In 
addition, in quartile analysis, women with the smallest measurements 
consistently reported the fewest number of bleeding/spotting days. No 
significant correlations between uterine size and bleeding were found 
among copper IUD users (Figure 9). 
Uterine size was also tested against reported spontaneous 
bleeding and no significant relationships were found. However, there 
was a trend towards women reporting scanty bleeding having 
measurements below the median, while the distribution among women 
with normal or heavy bleeding was more even. When dividing by 
quartiles, the measurements in women with scanty bleeding were 
equally distributed between the 1st and 2nd quartiles.  
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Figure 8. Median numbers of days of bleeding/spotting among the LNG-IUS users as grouped 
by uterine size. Quartiles represent results by dividing each measurement into four equally wide 
size groups, with the number of women in each group varying. Significant differences are 
shown.  
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Figure 9. Median numbers of days of bleeding/spotting among the copper IUD users as grouped 
by uterine size. Quartiles represent results by dividing each measurement into four equally wide 
size groups, with the number of women in each group varying.. No significant differences were 
found.  
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Uterine size and pain  
Among LNG-IUS users, no correlation between reported pain and 
uterine size measurements, when analysed as continuous variables, 
were found in either reference period. When grouping by median 
measurements, women with smaller measurements reported less pain 
(Figure 10). In the 2nd reference period, again women in the smallest 
size quartile reported the least pain. As with bleeding/spotting days, 
those with the widest fundal width reported markedly more pain in 
comparison with other women. In multivariate analysis including 
menstrual pain and uterine measurements, increasing fundal width was 
still associated with intense pain (exceeding menstrual pain) in the 2nd 
reference period (p = 0.01). Dysmenorrhoea and severe dysmenorrhoea 
remained the only significant predictors of total days with pain in both 
reference periods when tested against all other measurements.  
Among copper IUD users neither uterine measurements 
(Figure 11) nor patient characteristics were significant predictors of pain.  
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Figure 10. Median numbers of days of pain among the LNG-IUS users as grouped by uterine 
size. Quartiles represent results by dividing each measurement into four equally wide size 
groups, with the number of women in each group varying. Significant differences are shown.  
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Figure 11. Median numbers of days of pain among the copper IUD users as grouped by uterine 
size. Quartiles represent results by dividing each measurement into four equally wide size 
groups, with the number of women in each group varying.  No significant differences were found.  
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STUDY ON UTERINE PERFORATION  
 
Incidence of perforation  
The incidence study involved 51 women treated for perforation with an 
LNG-IUS and 17 women with copper IUDs. As annual sales numbers 
were markedly higher for the LNG-IUS, the incidence of perforation was 
similar with both types of device, 0.4/1000 insertions.  
 
Insertion and patient characteristics 
General practitioners had inserted 27 (40%) and gynaecologists 22 
(29%) of the devices. Data on the inserting HCP was missing in 21 
cases (31%). Five devices (7%) had been inserted under general 
anaesthesia because of previous problems at insertion, or following 
curettage or hysteroscopy. These women had not delivered within the 
previous year. In 11 cases (16%) the hospital physician examining the 
woman at diagnosis had commented on extensive flexion of the uterus. 
Only one woman was nulliparous. In 45/68 cases (66.0%), 
the woman had delivered less than one year prior to IUD insertion 
(Table 10). One woman had delivered by Caesarean section more than 
three months prior to insertion; all other deliveries were vaginal. Thirty-
eight devices (55.9%) had been inserted less than six months post-
partum and 15 devices (22.1%) less than three months post-partum. 
Twenty-two women (32.3%) were known to have been breastfeeding at 
the time of IUD insertion and 17 breastfeeding women (25.0%) were 
amenorrhoeic. Breastfeeding women more often reported pain at 
insertion than women not breastfeeding (75% vs. 64%, p = 0.009).  
 
Clinical course of perforations  
The type of device could be specified in 75 cases, 54 women used the 
LNG-IUS (72%) and 21 women a copper IUD (28%). Complaints of 
abnormal bleeding, lower abdominal pain or both, in combination with 
missing threads or an adherent IUD led to diagnosis in all 53 
symptomatic women (71%, Figure 12). Asymptomatic women (n = 22, 
29%) were diagnosed at routine follow-up visits when threads were 
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missing or in relation to unintended pregnancy. Pregnancies (n = 11) 
occurred more often following perforation with a copper IUD (n = 7/21, 
33% of women) than with the LNG-IUS (n = 4/54, 7%, p = 0.009). One 
tubal pregnancy (LNG-IUS group) was diagnosed, while ten pregnancies 
were intrauterine. One woman had a miscarriage, seven chose 
termination and two continued their pregnancies successfully. The only 
patient with symptoms of infection (PID) had had the LNG-IUS inserted 
4 years prior to symptoms and presented with an unintended pregnancy. 
At surgery, however, the IUD was high up in the omentum and unrelated 
to any infection. 
 
 
 
Figure 12. Clinical symptoms of the 75 women diagnosed with perforation by 
the LNG-IUS (n = 54) or by a copper IUD (n = 21). The p-values reflect 
differences between the two device types. 
 
The median time from insertion to diagnosis was 5 months (0–69 
months). The onset of symptoms could be defined in 28 (53%) of the 
symptomatic patients. In 26/28 cases the symptoms were immediate 
(<24 h in 21 women and 1–5 days in five women), with complaints of 
pain and in six cases combined with abnormal bleeding. Only 12 of 
these women (46%) sought treatment within a month.   
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Diagnosis, treatment and findings at surgery 
The primary diagnostic examination was commonly vaginal 
ultrasonography (n = 70; 93%). To verify the diagnosis of a missing IUD, 
either abdominal X-ray (n = 57; 76%), hysteroscopy (n = 20; 27%), 
diagnostic curettage (n = 8, 11%) or a combination of these was carried 
out. Computerized tomography was used once, as ultrasonography and 
X-ray examination failed to reveal a clear location of the IUD. 
Laparoscopy was scheduled only after at least one of the diagnostic 
metohds mentioned above had been performed to confirm the 
diagnosis. A total of 23 women (31%) underwent multiple procedures, 
hysteroscopy or curettage prior to abdominal surgery.  
The location of the IUDs and operative findings are shown 
in Table 15. In addition to 67 intra-abdominal IUDs, two IUDs that 
partially perforated the uterus were removed byway of laparoscopy. One 
intra-abdominal device was removed during a Caesarean section. Five 
intra-mural or partially perforating devices could be removed by way of 
hysteroscopy.  
 
 
  
Table 15. Findings at laparoscopic surgery. 
Location of IUD n (%) 
Adhesions at surgery n (%)* 
All women 
21/70 (30) 
LNG-IUS 
10/51 (20) 
Copper IUD 
11/19 (58) 
Intra-abdominal: 68/75 (91) 20/68 (29) 10/50 (20) 10/18 (56) 
      -omentum 44/68 (65) 15/44 (34) 10/35 (29) 5/9 (56) 
      -pelvis: 24/68 (35) 5/24 (21) 0/15 (-) 5/9 (56) 
         -Pouch of Douglas 10/24 (42) 2/10 (20) 0/8 (-) 2/2 (100) 
         -near the ovaries 13/24 (54) 3/13 (23) 0/6 (-) 3/7 (43) 
         -bladderpouch 1/24  (4) 0/1 (-) 0/1 (-) - 
Embedded in utero 4/75  (5) 0/4 (-) - - 
Partially perforating 3/75  (4) 1/2 (50) 0/1 (-) 1/1 (100) 
* Women treated by way of hysteroscopy were excluded from adhesion calculations 
  (two intramural LNG-IUSs, two intramural copper IUDs, one partially perforating LNG-IUS) 
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Surgical findings were mainly minimal. Adhesions were found in 7 (35%) 
of the asymptomatic women and in 14 (28%) of the symptomatic 
women. Women with a copper IUD had significantly more adhesions 
than women with an LNG-IUS (p = 0.002, Table 15). All adhesions in 
connection with copper IUDs were dense with the device embedded 
inside, but restricted to a small area around the device. In contrast, 
adhesions in connection with the LNG-IUS were filmy and in 4/10 cases 
(40%) unrelated to the location of the device. Adhesions were most 
common in women treated 1–6 months after insertion. No IUD-related 
infections were diagnosed, but four cases of sterile inflammation 
involving a copper IUD were found. In four women who experienced with 
acute pain at insertion, small haematomas and uterine erythema were 
seen in relation to the recent perforation. No intestinal or vascular 
complications were found. 
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9. DISCUSSION 
 
Intrauterine contraception in nulligravid women  	  
We found nulligravid women to be satisfied users of intrauterine 
contraception. Nine out of ten insertions were classified as easy, which 
is similar to (Suhonen et al. 2004, Brockmeyer et al. 2008) or higher 
than findings in prior studies (Bahamondes et al. 2011b, Marions et al. 
2011). In studies with higher rates of difficult insertions, a large 
proportion of HCPs have commonly been involved in performing the 
insertions. In this study, one experienced gynaecologist inserted all 
IUDs, eliminating inexperience and differing assessments as 
confounding factors.  
Insertion difficulties were mainly related to a tight cervix. 
The difference between the rates of easy insertions, 86.4% in the LNG-
IUS group vs. 94% in the copper IUD group, is equal to the difference 
seen when comparing the new smaller LNG-IUS 13.5 mg with the earlier 
device (Gemzell-Danielsson et al. 2012). The diameters of the NovaT 
and LNG-IUS 13.5mg insertion tubes are similar and approximately 1 
mm smaller than that of the earlier LNG-IUS, giving a difference of 2 mm 
in tube circumference, thus suggesting that this is the main reason for 
the difference in difficulties. 
Although the vast majority of insertions were easy, severe 
pain was common. The proportion of women reporting severe pain was 
significantly higher than in prior studies (Suhonen et al. 2004, Hubacher 
et al. 2006, Jensen et al. 2008, Marions et al. 2011). This difference may 
be accounted for by the timing of pain assessment, which here was 
immediately after insertion. This has previously been shown to affect 
pain assessment, with pain reported after three minutes being 
significantly less than immediate pain (Goldstuck et al. 1985). Most 
women report the intensity of pain at insertion as being similar to 
menstrual pain and the duration of pain as very short (Brockmeyer et al. 
2008, Marions et al. 2011). In addition, the majority of women would 
undergo IUD insertion again and also recommend it to their friends, 
regardless of pain (Rapkin et al. 2014).  
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 Results from diaries and follow-up were comparable to 
those from earlier similar studies on parous women. Similarly to parous 
women, bleeding/spotting days were frequent during the first month with 
both devices. As also reported in parous women (Andersson et al. 1994, 
Suvisaari and Lähteenmäki 1996, Jensen et al. 2008), bleeding/spotting 
thereafter stabilized in connection with the copper IUD, while continuing 
to decrease to 0-2 days per month among LNG-IUS users at the end of 
the study. Reports on pain followed the same pattern. Although bleeding 
disturbances were common with both devices during the first months, 
none discontinued before the 3-month follow-up visit, reflecting 
successful counselling. In addition, we found no pregnancies and low 
expulsion rates, additionally supporting the suitability of IUC in 
nulligravid women. 
The continuation rate at one year was similar to or 
somewhat lower than that in earlier studies (Brockmeyer et al. 2008, 
Bahamondes et al. 2011b, Behringer et al. 2011, Marions et al. 2011). 
However, only around 11% discontinued because of an adverse event. 
Despite attempts to contact all women not attending follow-up visits, 
some 18% were lost to follow-up with no verification of the status of the 
IUD one year after insertion. These women had moved to other parts of 
the country. In studies in which nulligravid or nulliparous women using 
the LNG-IUS have been compared with parous women, parity has not 
affected continuation rates (Bahamondes et al. 2011b, Berenson et al. 
2013). In the few trials where T-shaped copper IUDs have been 
compared in women of different parities, similar results have been 
reported (Sivin and Stern 1979, Petersen et al. 1991). Although the 
difference was small, we found a somewhat higher continuation rate with 
the LNG-IUS than the copper IUD, similarly to recent U.S. studies in 
which the slightly longer copper IUD, the TCu380A, has been used 
(Berenson et al. 2013, Aoun et al. 2014). Differences in bleeding have 
not been reported among women of different parities or ages using 
either type of device. One recent study with the LNG-IUS and the 
TCu380A (Aoun et al. 2014) revealed that nulliparous women reported 
more pain, but the device was not specified. Studies involving only the 
LNG-IUS have revealed no such difference between women of different 
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parities. When assessing only age, no difference in reported pain can be 
found between adult women of different ages (commonly divided </≥ 25 
years of age), with either device type. However, adolescents report pain 
and discontinue more often as a result of pain connected with the 
TCu380A, but not the LNG-IUS (Peipert et al. 2011, Berenson et al. 
2013). The findings may reflect either menstrual characteristics, inability 
to tolerate levels of bleeding or pain normally associated with IUDs, or 
the smaller uterine size in adolescents causing problems with the longer 
device, as adolescents have a smaller uterine size than adult nulliparous 
women (Gadelha da Costa et al. 2004).  
The higher continuation rates with the LNG-IUS observed in 
all women most likely reflect the differing mechanisms of the devices, as 
women using the LNG-IUS generally report lighter bleeding and less or 
similar cramping versus before the IUD, in contrast to copper IUD users. 
This greatly affects user satisfaction, positively for the LNG-IUS and 
negatively for the copper IUD, as increased bleeding and cramping are 
the leading reasons for discontinuing (Grunloh et al. 2013, Diedrich et al. 
2014).  
 
Dysmenorrhoea 	  
Severe dysmenorrhoea was the only factor predicting severe pain at 
insertion and also the only factor statistically significantly associated with 
reported days of pain during long-term use. Thus, interviewing women 
as regards menstrual characteristics provides a predictor of insertion 
pain and a means of counselling women on the expected pain profile at 
insertion and during the first few months. Counselling lowers anxiety at 
insertion, lowering expected pain (Allen et al. 2014), which again lowers 
actual pain (Goldstuck et al. 1985). Counselling about expected changes 
in menstruation also increases continuation and satisfaction rates during 
long-term use (Backman et al. 2002).  
The finding that dysmenorrhoeic women reported more pain 
at the beginning of IUD use was expected. Dysmenorrhoea is 
associated with uterine hypercontractility (Dawood 1985) as well as an 
altered response of the central nervous system to pain (Vincent et al. 
 72	  
2011), explaining the increased response to the uterine irritation caused 
by the IUD. Although the number of days with pain increased with 
increasing intensity of menstrual pain during the first months, the effect 
was small during the second reference period. The median number of 
days with pain was still related to the level of menstrual pain, but days 
with pain had decreased significantly more in women with 
dysmenorrhoea, especially in those with severe dysmenorrhea. Women 
using the copper IUD reported a clearly higher number of days with pain 
during the second reference period, with no difference in comparison 
with the intensity of menstrual pain before the IUD. The differing findings 
are again related to the mechanism of action of the devices, as the LNG-
IUS gradually decreases contractility with the gradual suppression of the 
endometrium, while no such transformation is seen in connection with 
copper IUDs. 
 
Uterine size – effect on insertion and long-term use  	  
Menstrual diary and insertion data have not previously been compared 
with uterine measurements. The ultrasonographic measurements in the 
present study were smaller than the studied devices (32 x 32mm) in a 
majority of the women. Both cavity length and fundal width were smaller 
than in prior ultrasonographic studies (Benacerraf et al. 2010, Canterio 
et al. 2010). The measurements were drawn as straight lines on pictures 
of slightly curved uteri, giving at least length measurements smaller than 
the actual size of the uterus. This, however, is the measuring technique 
normally used in clinical settings. With the exception of one woman with 
the insertion cancelled due to a hypoplastic 4.5-cm-long uterus, the 
sound measure was ≥ 6.0 cm in all subjects. In contrast, the length 
evaluated by ultrasonography was 45–60 mm in numerous women. 
Thus, the sound measure, following the curvature of the uterus gives a 
more reliable evaluation. We observed surprisingly small fundal width 
measurements, the median being 9 mm smaller than the width of the 
studied devices, but saw no negative results of small width with either 
device. In contrast, the only significant finding was increased intense 
pain in long-term use among LNG-IUS users with fundal width 
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measurements in the highest quartile. The precise correct point of 
measuring width is challenging to determine and thus the observed 
narrow width measurements are unlikely to reflect the true functional 
width of the uterus. In addition, as the frames of the studied devices are 
highly flexible, the device is likely to flex and adapt to the uterine cavity.  
  We found a correlation between difficult insertion and small 
total uterine length and steep flexion angle; a novel finding. However, 
the majority of insertions in small and flexed uteri were uneventful, 82–
83% in comparison with 95–96% in women with measurements above 
the medians of both parameters. Thus, this finding cannot be considered 
a significant predictor restricting IUD insertion. This conclusion is 
strengthened by the fact that no significant findings were revealed after 
dividing the measurements into quartiles and no good predictive 
threshold measurements were found in ROC analysis. In addition, the 
proportion of easy insertions observed with the NovaT measuring 32 x 
32mm was equal to that with the new smaller LNG-IUS 13.5mg, 
measuring 28 x 30mm (Gemzell-Danielsson et al. 2012), further 
indicating that cervical tightness and not uterine size is responsible for 
the majority of difficulties at insertion. A steep flexion angle does 
propose a challenge at insertion in any woman, but with an adequate 
technique, anatomical knowledge and straightening of the uterus at 
insertion, the flexion angle can usually be overcome, as recommended 
in practical guidelines (Bahamondes et al. 2013, Kaunitz and Nelson 
2014).  
 
Summary and clinical implications 	  
The findings in this study support the fact that small uterine 
measurements are not a contraindication to IUD use. Results do not 
support that smaller IUDs should be preferred among adult nulligravid or 
nulliparous women. Small uterine size observed in pre-insertion 
ultrasonography did not predict a worsened clinical outcome. Measuring 
the uterus with ultrasonography may give a false impression of a small 
uterus and thus prevent women from using IUC. Although uterine size 
has not been evaluated before, numerous recent studies have 
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repeatedly shown encouraging positive results in nulligravid/nulliparous 
women using both types of IUC, results similar to and strengthened by 
our own. Nulligravid and nulliparous women have not been compared 
against each other as regards IUC, but usually studied as one group. 
However, the results of studies defining all participants as nulligravid do 
not differ from those including both nulligravid and nulliparous women. 
The finding in our study that women with the smallest uteri reported less 
bleeding and pain with the LNG-IUS in comparison with other women is 
encouraging and also positive as regards adolescent users. Although we 
did not find any clear differences between women with differently sized 
uteri using the copper IUD, there was a slight trend towards more pain in 
long-term use among women with small measurements. As the study 
population was only half the size of the LNG-IUS population, and groups 
in quartile analysis were small, this may confound the results. 
Nevertheless, the finding may also explain the higher discontinuation 
rates related to pain among adolescents in other studies. The TCu380A 
in these studies is 4mm longer than the NovaT used in our study and 
adolescents have smaller measurements than adult women of similar 
parity (Gadelha Da Costa et al. 2004). However, discontinuation among 
adolescents may also reflect the fact that they more easily discontinue 
any form of contraception in comparison with adult women (Rostenstock 
et al. 2012). 
 
Age at first delivery has steadily increased in all developed countries, 
and is currently nearing 30 years. The average fertility rate is 1.5 to 2.5 
children/woman (OECD 2011-2014, THL 2014a, Oliveira da Silva et al. 
2011). Thus the average woman needs contraception throughout the 
majority of her fertile years, half of them spent as nulligravid/nulliparous. 
Acceptance and satisfaction with current intrauterine devices is not a 
problem in any age or parity group, as shown in the Contraceptive 
CHOICE project. Providing contraceptive counselling and any form of 
contraception cost-free has shown the importance of these factors in 
increasing contraceptive efficacy, especially among adolescents and 
young women, thus reducing costs and the subjective burden of 
unplanned pregnancies (Winner et al. 2011, Peipert et al. 2011, Peipert 
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et al. 2012, Secura et al. 2014). However, there is still a need to counsel 
women on contraceptive options, as prior studies in addition to the 
CHOICE project, have shown an increased prevalence of IUC in women 
with the best knowledge of contraceptive methods (Gemzell-Danielsson 
et al. 2013a). This is best achieved by educating HCPs, as 
misconceptions and poor knowledge of current positive 
recommendations regarding IUC in young women remains a barrier 
(Stubbs and Schamp 2008, Fleming et al. 2010, Tyler et al. 2012).  
 
Uterine perforation 	  
Women with IUD-related perforation represented typical IUD users, 
parous women in their 30’s. Thus a nulliparous woman is not a typical 
risk patient in this regard, despite a larger proportion of difficult 
insertions in this group. This is supported by the outcome of other 
studies with only a minimal proportion of nulliparous women 
represented. However, as nulliparity has been seen as a 
contraindication to IUD insertion in the past, this does create a bias. 
We found the incidence of perforation to be low and similar 
with both types of IUC. Rates were similar to or somewhat smaller than 
those in prior reports. Although the nature of the study enabled only an 
observation viewpoint, findings on patient characteristics are in line with 
those of the majority of previous studies, both case-control (Heartwell 
and Sclesselman 1983, Caliskan et al. 2003,) and observation 
(Andersson et al. 1998, Haimov-Kochman et al 2003b, van 
Haudenhoven et al. 2006) in which the post-partum period and lactation 
(Heartwell and Schlesselman 1983, Heinemann et al. 2014) have been 
identified as independent risk factors. Insertion during the post-partum 
period is generally considered easy, as the cervix is usually soft and 
wide. Prior reports have also suggested the procedure to be painless in 
lactating women, with perforation occurring more easily and even 
unnoticeably, without the woman complaining of pain (Chi et al. 1989). 
In our study this was not confirmed, as lactating women reported pain 
more often than non-lactating women. With involution of the uterus in the 
post-partum period, making it smaller, softer and thinner, as well as the 
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oxytocin-induced contractility related to lactation (Andersson et al. 
1998), both early and late perforation are possible. Extensive forces 
markedly exceeding average insertion forces are needed to perforate 
the uterus (Goldstuck and Wildemeersch 2014). Thus, immediate 
perforation in connection with an adequate insertion technique is 
unlikely. Forces needed to perforate an involuted uterus are presumably 
smaller. 
We did not identify severe adverse events caused by 
perforation, although a few women underwent laparoscopy soon after 
the diagnosis as a result of acute pain. The only acute adverse event 
identified was a bleeding ectopic pregnancy. In this study, the mild or 
absent symptoms and unexpected pregnancy leading to diagnosis are in 
line with other similar studies. Life-threatening intestinal or vascular 
complications have been linked to IUD models of closed shape (Zakin et 
al. 1981a), although non-threatening intestinal embedment has been 
described with all copper models as well as the LNG-IUS. The current 
models are flexible, blunt and non-irritating, thus minimizing the 
inflammatory and erosive effect of the perforating device. Similar rates of 
adhesions in connection with the NovaT have been described before 
(Caliskan et al. 2003). No studies describe severe adhesions in 
connection with the LNG-IUS. The difference in pregnancy rates related 
to the device types can be explained by the mechanisms of action of the 
devices. In a pharmacological case report study describing an omental 
LNG-IUS, a 10-fold increased plasma level of LNG compared with levels 
seen with the device in utero, was explained by the extensive vascularity 
of the omentum, enabling easy absorption. The LNG plasma level was 
similar to that seen with progestin pills, and thus anti-ovulatory (Haimov-
Kochman et al. 2003b). Similarly, anti-inflammatory and 
immunosuppressive effects of progesterone may reduce adhesion 
formation with a perforating LNG-IUS (Haimov-Kochman et al. 2003a). 
In contrast, the local sterile inflammation initiated by copper-releasing 
devices is presumably predisposing to adhesion formation outside the 
uterus. When this local effect is absent from the uterine cavity and 
copper levels in the genital tract are low, the contraceptive effect is 
easily lost. Thus, an alternative contraceptive is needed immediately 
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after diagnosis of perforation. Conversely, as the removal of intra-
abdominal IUDs in asymptomatic women has been questioned, at least 
women desiring pregnancy should have the device removed, as it may 
prevent pregnancy. 
 
Strengths and limitations 
 
Study on nulligravid women 
All nulligravid women requesting IUC in public health care in Helsinki are 
referred to the Family Planning Clinic. As IUC in this group of women is 
still minimal and the great majority of Finnish women opt for the LNG-
IUS, our enrolment period was markedly prolonged and finally stopped 
at 19 months. The aim of having two equally sized IUD groups could not 
be achieved, and thus comparison of the outcomes between the two 
IUD groups is weakened. Similarly, as the copper IUD group is small, 
analysis of diary data is significantly weakened in this group. 
The fact that all women were treated at one clinic, and by 
one physician, strengthens the results. By using only one physician, 
inter-observer differences could be eliminated as a confounding factor. 
Thus, all subjects were evaluated equally, strengthening both collection 
of background and insertion data and leading to uniformity of the 
insertion technique and ultrasonographic evaluation of the uterus. The 
expertise of the gynaecologist, however, weakens generalization 
regarding the rate of uneventful insertions, as inserter experience is a 
factor repeatedly shown to influence the ease and success of IUD 
insertion.  
Uterine measurements were taken using a standard 2-D 
ultrasonographic measuring technique. Measurements were taken only 
once and by one person. The pictures were, however, inspected and 
measurements read from them by another physician. Thus, 
measurements were validated by two physicians separately and any 
images of poor quality were excluded from size analyses. Repeatability 
of the same measurements, however, cannot not be assessed, since the 
procedure was carried out only once. 
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As the age of the women ranged from 18 to 43, generalizing 
the results to apply to the youngest women can be questioned. 
However, no significant differences in uterine size or clinical outcome 
were found when dividing the women into age groups (<20, 20–24, 35–
35 and >35 years, data not shown). 
 
Perforation study 
As uterine perforation with an IUD does not have its own ICD-10 code 
this limits proper identification of patients as physicians may use 
differing codes for the same procedure. Operative codes related to 
foreign objects are, however, precise and thus we can be reasonably 
confident to have included all surgically treated IUD-related perforations 
in the study. In addition, the registry used to identify patients was not 
limited to gynaecological patients. Thus, records of women treated by 
abdominal surgeons, coded with diagnoses related to removal of a 
foreign object could be checked to verify if the case involved an IUD. 
 The proportion of patients treated in the study area was 
29% of nationwide-identified cases, which is equal to the proportion of 
IUDs sold in the area and to the proportion of the Finnish population 
living within the study area. Incidence calculations therefore represent a 
reliable estimate of nationwide numbers and symptoms, and surgical 
findings a good population-based overview of the clinical course of IUD-
related perforations.  
The study is limited by its retrospective nature. With IUDs 
inserted mainly outside hospitals and no access to records outside 
treating hospitals, analysing factors at insertion (both physician- and 
subject-related) possibly predisposing individuals to perforation was 
limited to notes made at the hospital where treatment was carried out. In 
addition, the lack of controls weakens the analysis of patient 
characteristics. With IUDs inserted in multiple healthcare settings and 
with reliable information on the insertion lacking among some of the 
subjects, identifying appropriate controls could not be achieved.   
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10. CONCLUSIONS 
 
IUD use in nulligravid women 	  
• Nulligravid women are satisfied IUD users. The majority of 
insertions are easy and uneventful, but pain is common. 
Continuation rates are similar to those in parous women. Days 
with bleeding and pain as well as adverse events are similar to 
those in parous women.  	  
• Dysmenorrhoea is the only predictor of pain. Severe 
dysmenorrhoea predicts severe pain at insertion and women with 
dysmenorrhoea experience more pain during IUD use, especially 
during the first months. Counselling and sufficient analgesia at 
insertion in these women should be emphasized. 
 
Uterine size and intrauterine contraception 	  
• Small uterine length may increase risk of insertion difficulties, but 
not pain at insertion. Nevertheless, the majority of insertions in 
women with small uteri are uneventful and cervical tightness is 
the main reason for difficulties. 	  
• Smaller uterine size in nulligravid and nulliparous women is not a 
barrier to modern intrauterine contraception. Instead, LNG-IUS 
users benefit from small size in long-term use as regards both 
bleeding profile and pain. 	  
• Ultrasonographic evaluation of uterine size prior to insertion is not 
necessary to make clinical decisions. Clinical evaluation including 
pelvic examination and sound measure are sufficient.  
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Uterine perforation 	  
• The perforation rate is low and similar with the LNG-IUS and 
copper IUDs.  	  
• A large proportion of perforations occur during the post-partum 
period. However, the risk is small and this should not limit the use 
of intrauterine contraception in these women. 
 
• Symptoms associated with a perforating modern flexible T-
shaped polyethylene device are rarely severe. Abnormal bleeding 
and abdominal pain are the most common symptoms, but many 
women are asymptomatic. 	  
• Pregnancy is a common symptom of a misplaced copper device, 
but it is rare with a misplaced LNG-IUS.  
 
• Misplaced devices are commonly found in the omentum, if not 
around the uterus. Adhesions are rare in connection with the 
LNG-IUS and if found, mainly filmy. A misplaced copper device is 
commonly surrounded by local adhesions.  
 
• Surgical treatment of asymptomatic perforation has been 
questioned. However, as the device may act as a contraceptive, 
the LNG-IUS in particular should be removed if pregnancy is 
desired. 
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